Cancer in Nunavut: 1999-2011
Cancer in Nunavut: 1999-2011
Prepared By:
Population Health Information Department of Health
Government of Nunavut P.O. Box 1000, Station 1033
Iqaluit, NU X0A 0H0 [email protected]
Fall, 2014
2
Table of Contents
Executive summary………………………………………………………….. 3
Background: Nunavut cancer risk factors………………………….. 4
Cancer overview………………………………………………………………. 6
Specific cancer information
Lung and bronchus cancer……………………………………… 7
Digestive system……………………………………………………. 11
Urinary system………………………………………………………. 19
Gynecological cancer……………………………………………… 20
Male reproductive cancer………………………………………. 23
Hematopoietic and lymph node cancer………………….. 25
Thyroid and other endocrine…………………………………. 26
Brain……………………………………………………………………… 26
Connective and soft tissue can- 26
Unknown cancers………………………………………………….. 26
Summary………………………………………………………………………….. 27
Recommendations……………………………………………………………. 27
References……………………………………………………………………….. 28
Appendices
Appendix A: Data sources………………………………………. 34
Appendix B: Cancer site classification: ICD-O-3………. 35
Appendix C: Methodology……………………………………… 36
Cancer in Nunavut: 1999-2011 3
Executive Summary Cancer is the leading cause of mortality in Nunavut and is a significant cause of illness with an average of 59 cases per year from
1999 to 2011.105 Although the 2011 numbers are preliminary, the age-standardized incidence rate (ASIR) of cancer for Nunavut in
2011 was 362.3 per 100,000 as compared to the Canadian rate of 406.0 per 100,000.15 The epidemiology of cancer in Nunavut is
distinct from Canada in leading cancers as well as gender distribution.
Nunavummiut experience higher rates of lung, colorectal, oral and digestive cancers and lower rates of reproductive, hematopoiet-
ic, bladder and thyroid cancers than Canadians. The top 5 cancers affecting Nunavummiut between 1999 and 2011 are: (1) lung, (2)
colorectal, (3) breast, (4) oral and (5) prostate. These cancer groups account for 68% of all cancers. The female Nunavummiut ASIR
exceeds the national rate by 30%, while the male Nunavummiut ASIR is 52% lower than the national rate.15 These differences in
cancer rates may be attributable to variance in demography, heredity, health services, environmental exposures, lifestyles and
illness patterns.
There are multiple programs in place in Nunavut that address cancer risk factors. Amongst them are: Tobacco Reduction Strategy,
Nutrition North and Public Health immunization programs. Further efforts are required to promote healthy lifestyles and environ-
ments as well as to prevent chronic and communicable diseases. Accessible screening programs are also needed in communities to
enable early detection and treatment to improve prognosis.
List of Abbreviations ASIR Age standardized incidence rate
BMI Body mass index
COPD Chronic obstructive pulmonary disease
EBV Epstein-Barr virus
HPV Human papilloma virus
HTLV-1 Human T-cell lymphotropic virus type 1
ICD-10 International Classification of Disease, 10th
revision
ICD-O-3 International Classification of Diseases Oncology,
3rd revision
NWT Northwest Territories
TB Tuberculosis
4
Background: Nunavut cancer risk factors Nunavut is the largest, northern most territory in Canada with an 85% Inuit population. The population of 33,551 people is spread
over 25 fly-in communities covering 2,093,190 km2.
The demographic distribution of Nunavut differs
from Canada, with the majority of the population un-
der 25 years (Figure 1). The life expectancy of Nu-
navummiut at birth is trending up (72.1 years) but is
still 8.5 years lower than Canada (80.6 years).106 The
crude birth rate in Nunavut is 2.3 times the national
average and the total fertility rate is 1.8 times the na-
tional average.104
Healthcare service delivery is different in Nunavut
than the rest of Canada due to its remoteness. Each
community has a health centre with Community Health
Nurses who provide the majority of health services.
The average nurse to population ratio in communities
(excluding Iqaluit) is 1:268. There are 29.5 physician
positions, half of which are staffed by short-term locums, with permanent positions in Iqaluit, Rankin Inlet, Cambridge Bay and
Arviat.
If a patient’s condition exceeds the capacity of the health centre,
they are taken by medevac or scheduled medical travel to a major
health centre (Figure 2). There is generally no specialty diagnostic
equipment (e.g. mammography) or specialists (e.g. oncologists) in
most communities, impacting availability and timeliness of services.
Cancer screening, diagnosis and treatment often require travel, sep-
arating patients from their social networks within communities.
Housing has health impacts influencing communicable disease
transmission and environmental contaminant exposure (e.g. envi-
ronmental tobacco smoke). Nunavut households are more crowded,
having an average of 3.7 people per household compared to 2.5
people in the rest of Canada, potentially affecting cancer risk.65, 103
Contaminant concentrations in the Arctic are affected by global wind and water patterns, bioaccumulating in marine mam-
mals.38 Contaminants found include: (1) polychlorinated biphenyls (PCBs), (2) pesticides, (3) organochlorines and (4) heavy metals
(e.g. mercury).38 Pollutants can affect cancer risk by mimicking hormones and interacting with nutrients and other contaminants.38
Physical activity level has decreased due to a western lifestyle. Canadians were 7% more physically active during leisure-time
than Nunavummiut.109 Males were consistently more physically active in both the Canadian and Nunavut population, with the ex-
ception of non-aboriginal males in Nunavut.109 Inuit in Nunavut were 10% more active than their non-aboriginal Nunavummiut
counterparts.109 Overall, Nunavummiut have significantly lower levels of physical activity than Canadians, potentially contributing
to the higher rate of some cancers.108
Figure 2. Medical travel patterns59
Figure 1. Age-groups as a percentage of total population, Canada and Nunavut, 2011101
Cancer in Nunavut: 1999-2011 5
Dietary patterns in Nunavut have historically been distinct from Canada; this pattern is currently in flux.39, 96, 110 Traditional
foods are high in nutrients including macronutrients, vitamins, antioxidants and minerals.55, 66, 67 In a western diet, fruits and vege-
tables are an important nutrient source. As refined, store bought foods become a bigger part of diets, there is a loss of the tradi-
tional source of nutrients without replacement with fruits and vegetables.68, 96, 108 Nunavut’s rate of fruit and vegetable consump-
tion is consistently, significantly lower than the national age-standardized rate (ASIR) by an average of 75%.108
Further complicating nutrition in Nunavut is food insecurity, which impacts overall diet quality.58 The ASIR for those living with
moderate or severe food insecurity in Nunavut is 37.8 per 100,000, which is 5 times higher than the national average.109 Diet is an
important protective factor in cancer prevention; poor diet quality and nutrient deficits may contribute to higher cancer rates.
Substance use in Nunavut is distinct from Canada, specifically tobacco and alcohol use. Nunavut exceeds the Canadian ASIR for
current daily or occasional smokers by 3.4 times with 60% of the population smoking. Inuit in Nunavut smoke 1.4 times more than
Inuit in Canada, and non-aboriginals in Nunavut smoke 1.6 times more than Canadians.109 The smoking rate is 14% higher for Nu-
navut females than males, unlike Canada where the male rate exceeds the female rate by 31%. Ninety percent of households in
the Inuit Health Survey had at least one smoker with individuals smoking an average of 10-13 cigarettes per day.39 The higher to-
bacco use in Nunavut is reflected in the higher rate of some cancers.
Alcohol is controlled in Nunavut; some communities prohibit alcohol and others regulate it. The reported Nunavut ASIR for heavy
drinking ( ≥5 drinks per occasion at least monthly in the past year) is 4% lower than Canada for the 10 communities included.109
Males in both national and territorial populations have a higher rate of heavy drinking.109 Within Nunavut, the non-aboriginal pop-
ulation exceeds the Inuit population by 1.4 times for heavy drinking.109 Literature indicates more heavy drinking in aboriginal and
Inuit populations; however, Inuit in Nunavut have a 55% lower rate of heavy drinking than Inuit outside Nunavut.78, 109 Heavy
drinking is only one measure of alcohol use and does not describe binge drinking, moderate use or chronicity of alcohol use.
Infection is an important contributor to the burden of cancer. In 2008, diagnosed cancers attributable to infection was globally
16.1% (7.4% for developed regions and 22.9% for developing regions).36 The primary communicable diseases impacting cancer risk
in Nunavut are: (1) tuberculosis (TB), (2) human papilloma virus (HPV), (3) Epstein-Barr virus (EBV), (4) viral hepatitis, (5)
Helicobacter pylori (H. pylori) and (6) human T-cell lymphotropic virus type 1 (HTLV-1). 39, 80, 82, 90, 99 Nunavut has patterns of com-
municable disease that differ from Canada, potentially contributing to higher rates of some cancers.
Chronic conditions are thought to affect cancer risk through inflammation and impact on the endocrine system.11 Diabetes
incidence in Nunavut has remained relatively stable between 2005 and 2011 and does not significantly differ from the national
rate.108 Overall, in 2011 diabetes had a 3.1% prevalence in Nunavummiut.88 Chronic obstructive pulmonary disease (COPD) has
trended down between 2005 and 2011.88 The 2011 ASIR for Nunavut was 23.7 per 100,000, which is 6.2 times higher than the na-
tional average.108 Overall, in 2011 COPD had a 14.3% prevalence in Nunavummiut.88
Adipose tissue is active endocrine tissue that affects hormone levels. Therefore, excess body fat can impact cancer risk.11 From
2003 to 2012, people who are overweight or obese has steadily trended up in Canada with an average ASIR of 49.6 per 100,000.108
Nunavut sporadically exceeds the Canadian ASIR with a rate fluctuating between 52.7 and 63.7 per 100,000, which is on average
1.2 times higher than the national rate.108 Only Nunavut’s female rate is consistently, significantly higher than the national female
rate.108 The rate of chronic conditions is likely mirrored in the increased rate of some cancers in Nunavut.
6
Cancer overview Approximately 40% of Canadians will develop cancer and it is also the national leading cause of death.16 Nationally, lung, breast,
colorectal and prostate cancers account for 52% of cases and cancer is the fourth most costly disease accounting for $2.6 billion in
direct healthcare costs.16
A total of 773 Nunavummiut (405 female, 368 male) were diagnosed with cancer between 1999 and 2011. For Nunavummiut, can-
cer was the leading cause of death between 2000 and 2009. During this period Nunavut’s age-standardized mortality rate exceeded
the national rate 2.2-fold.105
The cancer pattern among Nunavummiut is different than Canadians (Figure 3). Comparing the Canadian and Nunavut ASIR, lung,
oral and digestive cancers exceed the national rate whereas reproductive and hematopoietic cancers are lower, a finding consistent
with other circumpolar regions.42 In 2011, the all-cancer ASIR was lower for Nunavummiut (362.3 per 100,000) than Canada (406.0
per 100,000).15 The gender-specific ASIR patterns differed with Nunavummiut females exceeding Canadian females by 30% (481.4
versus 369.0 per 100,000) and with Nunavummiut males having a 52% lower rate (239.4 versus 456.0 per 100,000) than Canadian
males.15
Overall, both Nunavut and Canada have lung, colorectal and breast or prostate cancer in the top 5 cancers. The leading 5 sites for
females nationally are: breast, lung, colorectal, body of uterus and thyroid.15 Whereas the leading 5 sites for females in Nunavut
are: lung, colorectal, breast, oral and kidney.
Canadian females appear to be more affect-
ed by reproductive cancers while Nu-
navummiut females appear to be more af-
fected by lung and colorectal cancer.
The leading 5 sites for males nationally are:
prostate, lung, colorectal, bladder and Non-
Hodgkin lymphoma.15 The leading 5 sites for
males in Nunavut are: lung, colorectal, oral,
prostate and kidney. Canadian males appear
to be more affected by reproductive cancers
while Nunavummiut males appear to be
more affected by lung and colorectal can-
cer.
Since cancers have a long latency period,
current cancer trends are reflective of fac-
tors prevalent in the population decades
ago. With changing lifestyles and diet, it is
likely that cancer patterns will change as
Lung Colorectal Oral Esophagus Stomach Kidney Bladder Liver PancreasNon-Hodgkin
LyphomaLeukemia Thyroid Brain Breast Cervix Uterus Testis Prostate
2.93 1.42 2.82 2.94 0.19 1.67 0.26 0.49 2.44 0.30 0.05 0.24 0.61 0.61 0.94 0.13 1.58 0.32
0
1
2
3
4
Ra
tio
Figure 3. Ratio of Nunavut 3 year moving average and Canadian age standardized incidence rate, 2011
Higher Canada Rate
* Unable to calculate rate ratio for: Hodgkin's Lymphoma, Multiple Myloma, Melanoma and Ovary as there were no Nunavut cases.
42%34% 39%
25%
20%
23%
19%
10%
8%
6%
7%8%
4%4%5%
5%2%
5%4%
5%
3%3% 2%
3%3%3%2%
2%2%3%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Female Male Nunavut
Figure 4. Top 10 cancer groups*: Proportion by gender and Nunavut, 1999-2011
Lung Colorectal Breast** Oral Prostate Kidney Stomach Cervix Pancreas Esophagus Brain Leukemia Thyroid
* "Other" and "unknown" categories excluded from calculating top 10 cancer groups
** 1 male breast cancer case excluded from analysis
Cancer in Nunavut: 1999-2011 7
Lung & Bronchus Cancer
Lung cancer is the leading cancer amongst Nunavummiut with 247 cases (114 female, 133
male) accounting for 32% of reported cancer cases between 1999 and 2011. Other respiratory
tract cancers accounted for an additional 1% of reported cancer cases with 7 cases (3 female, 4
male) between 1999 and 2011.
Nunavut’s lung cancer rate is amongst the highest globally and is 3 times higher than the Cana-
dian rate.27, 107 The top three histologies are: squamous cell carcinoma (SCC), non-small cell
carcinoma, and unspecified small cell carcinoma . The development of lung cancer is complex
with risk factors working both independently and synergistically.
What are the risk factors for lung cancer?
1.
2.
3.
Family history of disease, independent of smoking, increases the chance of developing lung cancer 1.4-fold
[1.2-1.7].73 There are numerous genes and mechanisms implicated in the risk of developing lung cancer.33, 54
For example, the p53 gene mutation occurs in 33% of lung cancers and this percentage increases with tobacco
consumption.33, 54 Another example is genomic polymorphism of the XRCC1 gene, implicated in DNA repair,
which increased lung cancer chances 1.9-fold [1.3-2.9] independent of smoking.47
Gender also influences risk, not only for biological factors like hormones but also for gender-specific roles
that dictated exposure to carcinogens.29, 48 For example, women were more often exposed to environmental
tobacco smoke and men were more often exposed to occupational carcinogens.29
Infection and inflammation are well-established risk factors in cancer development, thus acute and
chronic illness as well as infectious diseases contribute to cancer risk.33
Acute illness in never smokers, like pneumonia history, increases cancer risk 1.4-fold [1.1-1.7]. For those with
chronic illness like COPD, chronic bronchitis or emphysema, the risk increases 1.5-
fold [1.2-1.9].9 In 2011, the Nunavut prevalence for COPD was 14.3%.88
Infectious diseases increase lung cancer risk independent of smoking: TB increases
risk 1.9-fold [1.5-2.5] and HPV increases the risk of SCC 3.5-fold [1.7-7.5].9, 19, 118 In
Nunavut, the average TB rate is 30 times the national rate; at this time the HPV inci-
dence rate is not available.88
In Nunavut, respiratory-related concerns are the primary reason for people access-
ing community health centres.88 The high occurrence of chronic and infectious diseases in Nunavut likely con-
tributes to higher lung cancer rates experienced by Nunavummiut.
Quick facts
Leading cancer site in Nunavut
Average of 19 cases per year
Average age at diagnosis 66 years
62% mortality within one year of diagnosis
8
Environmental Factors
Smoking is the primary etiologic agent implicated in lung cancer, increasing risk 20-fold, and is thought to be responsible
for up to 90% of cases in countries where smoking is common.2 Smoking also works synergistically with infectious diseases
and has been found to increase HPV susceptibility, further increasing lung cancer risk.19
Smoking has been found to alter gene expression and transcription.7 Many genes return
to near normal levels after smoking cessation; however, there are genes that are either
slow to recover or do not normalize even decades after smoking cessation.7 These find-
ings highlight the importance of both never smoking as well as smoking cessation.
Presently, 60% of Nunavummiut 12 years or older report smoking, which is 3 times the
Canadian average. The tobacco use rate in Nunavut is likely a major contributing factor
to the higher lung cancer rate experienced by Nunavummiut.
Carving is an important industry in Nunavut. With the introduction of power tools in
the 1980s, the health impacts have changed.113 Power tool users are exposed to 90 times more dust than non-users.113
This dust, whether it be rock or animal product, has been associated with res-
piratory inflammation.113
In a study of 75 of Nunavut’s carving rock quarries, four were noted to have
asbestos.6 Another study analyzing territorial rock samples found that 19% of
samples had tremolite and 7% of samples had chrysotile, substances that are
part of the asbestos family.113 Asbestos has long been linked to lung cancer
development.
A 2003 study of carvers found that only 58% wore dust masks.113 Of these
individuals, only 28% always wore a mask, 55% mostly to sometimes wore a
mask and 16% did not often wear a mask.113 Thus with technological changes,
rock composition and lack of personal protection, carvers are potentially at
increased risk of lung cancer.
Other environmental risk factors independent of smoking include: environmental tobacco smoke, which increases
risk 1.3-fold [1.2-1.4] and cooking oil fumes (moderate levels of cooking) which increases risk 3-4-fold [1.5-8.9].49, 111, 117
4.
Cancer in Nunavut: 1999-2011 9
What are lung cancer rates in Nunavut and how do we compare to the rest of Canada?
Are there regional differences in lung cancer rates across Nunavut?
Of all the regions, Baffin had the highest rate (76.3
cases per 100,000) followed by Kivalliq (50.6 cases per
100,000) and then Kitikmeot (44.5 cases per 100,000).
Looking at the number of cases, Baffin had the highest
proportion of cases (65%) followed by Kivalliq (22%)
and then Kitikmeot (13%).
The Nunavut ASIR has generally
trended down over time but still
significantly exceeds national and
NWT rates. In fact, the Nunavut
rate is 3 times higher than the
national rate.
Lung cancer rates are reflective
of smoking patterns, but lag
about 20 years.2 The noted
downward trend is thought to be
associated with historic efforts in
smoking cessation.2
Are there age-related trends in lung cancer incidence in Nunavut?
In Nunavut, the average age at diag-
nosis was 66.2 years (range 36-92
years, standard deviation 9.7 years).
35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
Incidence Rate 6.98 24.77 20.12 106.31 160.38 580.00 1248.961683.501926.781333.331244.81
0
500
1000
1500
2000
2500
Ra
te p
er
100
,00
0
Figure 7. Lung Cancer Incidence Rate per 100,000 by Age Group, Nunavut, 1999-2011
Nunavut Baffin Kivalliq Kitikmeot
Incidence Rate 63.29 76.34 50.62 44.50
0
10
20
30
40
50
60
70
80
90
Rat
e p
er 1
00,0
00
Figure 6. Lung Cancer Average Incidence Rate per 100,000 by Region, 1999-2011
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut* 258.75 297.06 313.51 284.12 256.68 217.56 220.85 179.09 161.72 164.33 157.49
NWT** 34.00 62.50 62.50 84.80 70.30 70.10 73.30 76.30 56.10
Canada^ 58.70 57.90 57.00 57.40 57.70 56.90 56.00 55.66 55.62 53.71 53.78
0
50
100
150
200
250
300
350
Rat
e p
er 1
00,0
00
Figure 5. Lung Cancer, Age-Standardized Incidence Rate per 100,000 for Canada, Nunavut and Northwest Territories, 2001-2011105
* 3-year moving average.**Data from CANSIM table 103-0553. Blank cells indicate unavailable data.^ Data CANSIM table 103-0553. 2008 data onward are estimates from personal communications with Public Health Agency of Canada.
10
Are there gender-related trends or differences in lung cancer rates in Nunavut?
Nationally, males have a significantly higher rate than females; this difference is consistent over time. In Nunavut, the male rate
slightly exceeds the female rate 2005 to 2010; however, the rate difference by gender does not significantly differ over time.
Compared to Canada, the Nunavut 2011 rate for females was 3.5 times higher and for males was 2.1 times higher; the magni-
tude of this difference by gender is also true for the overall Canadian Inuit population as compared to Canada.20 Within the
circumpolar region, the Canadian lung cancer incidence exceeds Alaska and Greenland by 1.5 times in men and 2-3 times in
women.27
What mortality data are available for lung cancer?
Death clearance data are obtained from Statistics Canada and are available for years 1999-2008. For Nunavummiut diagnosed
with lung cancer, 62% died within one year of diagnosis.
Discussion: What does this information mean for Nunavummiut?
Nunavummiut experience much higher rates of lung cancer as compared to Canada. Higher rates of infectious and chronic dis-
ease as well as tobacco use are likely major contributing factors to Nunavut’s lung cancer rate.
Creating smoke-free environments is important; legislated and home smoking bans effectively reduce nicotine dependence and
promote smoking cessation.4 Smoking bans are also shown to positively affect non-smokers, reducing presentation of inflamma-
tory lung conditions like asthma.4 Continued implementation of the Nunavut Tobacco Reduction Strategy is pivotal to reducing
cancer risk.
Further efforts in infectious and chronic disease prevention, smoking cessation and early detection are pivotal to curtailing lung
cancer rates and improving prognosis. However, impacts may take years to manifest due to a long latency period between risk
factor exposure and lung cancer development.
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut Female* 294.76 338.19 342.28 316.89 249.85 207.03 197.82 171.53 146.64 146.77 175.87
Nunavut Male* 242.10 277.70 309.15 275.42 273.30 222.94 238.88 186.41 180.06 182.88 139.32
Canadian Female** 45.10 45.70 45.60 46.30 47.60 47.90 47.20 51.00 47.00 48.00 51.00
Canadian Male** 77.00 74.50 72.40 72.30 71.10 69.10 67.80 67.00 66.00 66.00 65.00
0
50
100
150
200
250
300
350
400
Rat
e p
er 1
00,0
00
Figure 8. Lung Cancer, Age-Standardized Incidence Rate per 100,000 for Canada and Nunavut by gender, 2001-201112-15, 105
* 3-year moving average used**Data from CANSIM table 103-0553, with the exception of 2008-2011 data which are estimates obtained from Annual Canadian Cancer Society Reports.
Cancer in Nunavut: 1999-2011 11
Colorectal cancer is the second leading cancer affecting Nunavummiut, accounting for
19% of cancer cases diagnosed between 1999 and 2011. In the circumpolar region, colo-
rectal cancers account for 15% of Inuit cancer cases; this is expected to trend up with
changing lifestyles.27 Consistent with literature, the predominant histological type of
colorectal cancer in Nunavut is adenocarcinoma (91%).
What are the risk factors for colorectal cancer?
1.
2.
3.
4.
Hereditary factors are thought to contribute 12-13% to risk.34 Examples of known susceptibility genes
include: APC gene which is associated with polyposis, MSH2 and MLH1 genes which are implicated in non-
polyposis colorectal cancer syndrome.5 Family history impacts risk with a greater than 2-fold increase in risk
when at least one first-degree relative is diagnosed.5, 10 The risk of developing colorectal cancer after the age
of 40 years was calculated to be 4.7% [4.0-5.6%] for the general population and 9.6% [6.3-14.2] for those with
a family history of disease.10
Obesity (body mass index (BMI) ≥ 30 kg/m2 ) is consistently associated with higher risk of colorectal cancer
and is found to increase risk 1.2-fold [1.1-1.3].79 The risk is higher in men and is consistently higher in both
genders for developing cancers of the colon than rectum.11 For colorectal cancer, obesity is estimated to con-
tribute 28-35% in men and 14-21% in women for the United States and Europe.11 One analysis found that for
every 2kg/m2 increase in BMI there was an associated 1% increase in colorectal cancer risk.79
Chronic illness like inflammatory bowel disease is thought to increase risk.94 One meta-analysis deter-
mined risk for colorectal cancer increased 2.5-fold [1.3-4.7] with Crohn’s disease, with risk accumulating over
time.18 The results were similar for ulcerative colitis.18 Diabetes is also implicated in colorectal cancer risk; in
one meta-analysis where physical activity and BMI were controlled for, there was a 1.3-fold [1.2-1.5] increase
in risk.70
Lifestyle factors impact colorectal cancer risk. Alcohol has a dose relationship, increasing risk by 5% [1-9%]
for colon and 9% [8-12%] for rectal cancer with 25g/day and
21% [5-39%] for colon and 42% [30-55%] for rectal cancer
with 100g/day.32
Diet is correlated with colorectal cancer risk where fruit, veg-
etable and fish consumption is found to be protective (i.e.
decrease risk) and red meat consumption is found to in-
crease risk.41 Physical activity is also found to be inde-
pendently protective.50
Quick facts
Second leading cancer site in Nunavut
Average of 11 cases per year
Average age at diagnosis 60 years
26% mortality within one year of diagnosis
Digestive System:
Colorectal Cancer
12
What are colorectal cancer rates in Nunavut and how do we compare to the rest of Canada?
Are there regional differences in colorectal cancer rates across Nunavut?
Are there age-related trends in colorectal cancer incidence in Nunavut?
In Nunavut, the average age at
time of diagnosis 59.9 years.
However, age ranged between
23-90 years (standard deviation
13.7 years).
Of all the regions, Baffin had the highest rate (41.2 cases per
100,000) followed by Kitikmeot (34.8 cases per 100,000) and
then Kivalliq (30.4 cases per 100,000).
Looking at the number of cases, Baffin had the highest propor-
tion of cases (59%) followed by Kivalliq (24%), then Kitikmeot
(17%).
In Nunavut, there were 146
cases (68 female, 78 male) di-
agnosed between 1999 and
2011.
Overall, the Nunavut ASIR has
trended down over time and as
of 2011 it was 1.4 times higher
than the national rate.
With the exception of 2004,
2010 and 2011, Nunavut signif-
icantly exceeds the national
rate.
Nunavut Baffin Kivalliq Kitikmeot
Incidence Rate 37.29 41.23 30.37 34.84
0
5
10
15
20
25
30
35
40
45
Rat
e p
er 1
00,0
00
Figure 10. Colorectal Cancer Average Incidence Rate per 100,000 by Region, 1999-2011
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut* 147.13 126.55 113.35 75.85 108.61 118.16 143.79 104.77 88.56 61.07 69.89
NWT** 111.40 107.20 106.20 110.40 82.90 99.40
Canada^ 51.70 51.30 49.90 50.70 50.60 49.50 49.70 50.10 49.23 47.82 49.22
0
20
40
60
80
100
120
140
160
Rat
e p
er 1
00,0
00
Figure 9. Colorectal Cancer, Age-Standardized Incidence Rate per 100,000 for Canada, Nunavut, and Northwest Territories, 2001-2011105
* 3-year moving average.**Data from CANSIM table 103-0553. Blank cells indicate unavailable data.^ Data CANSIM table 103-0553. 2008 data onward are estimates from personal communications with Public Health Agency of Canada.
20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
Incidence Rate 2.91 8.91 3.14 17.44 24.77 85.51 112.22 168.40 201.74 395.50 561.17 642.26 1600.00 207.47
0
200
400
600
800
1000
1200
1400
1600
1800
Ra
te p
er
100
,00
0
Figure 11. Colorectal Cancer Incidence Rate per 100,000 by Age Group, Nunavut, 1999-2011
Cancer in Nunavut: 1999-2011 13
Are there gender-related trends or differences in colorectal cancer rates in Nunavut?
With the exception of 2002, colorectal cancer rates do not significantly differ between men and women. While the female rate
generally exceeds the male rate, this is not always the case. Nationally, the male rate significantly and consistently exceeds the
female rate. According to literature, there is an interaction between gender and BMI with obese men being 30% more likely to
develop colorectal cancer than obese women.11, 79
What mortality data are available for colorectal cancer?
Death clearance data are obtained from Statistics Canada and are available for years 1999-2008. For Nunavummiut diagnosed
with colorectal cancer, 26% died within one year of diagnosis.
Discussion: What does this information mean for Nunavummiut?
As there are changes in lifestyles and diet as well as a corresponding increase in chronic diseases, it is expected that colorectal
cancer rates will trend up.27 Promotion of healthy lifestyles as well as prevention and control of chronic diseases is paramount to
reducing risk.
Screening provides an opportunity for early case identification and improved prognosis. Targeted screening based on identified risk
factors and population-based screening is an efficient way to make a difference in colorectal cancer prognosis and to potentially
improve survival.
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut Female* 183.68 203.73 167.21 84.70 90.32 92.22 127.51 101.76 97.62 86.49 82.56
Nunavut Male* 120.60 70.90 78.44 72.37 124.71 138.47 156.30 107.51 77.37 36.49 57.28
Canada Female** 42.30 42.10 41.20 41.60 41.50 40.30 40.60 41.00 41.00 41.00 40.00
Canada Male** 63.20 62.60 60.30 61.50 61.40 60.40 60.50 62.00 62.00 62.00 61.00
0
50
100
150
200
250
Rate
per
100
,000
Figure 12. Colorectal Cancer, Age Standardized Incidence Rate per 100,000 for Canada and Nunavut by gender, 2001-201112-15, 105
* 3-year moving average used**Data from CANSIM table 103-0553, with the exception of 2008-2011 data which are estimates obtained from Annual Canadian Cancer Society Reports.
14
Quick facts
Within top 4 cancers affecting Nunavummiut
Average of 4 cases per year
Average age at diagnosis 52 years
9% mortality within one year of diagnosis
Digestive System:
Oral Cancer
Oral cancers are rare in most parts of the world, but common among Inuit as well as popula-
tions in Southern China and North Africa.27 Genetic markers in the Inuit population indicate
Asian heritage, thus oral cancer trends in Southern China are relevant to Nunavut’s popula-
tion.51, 62 In Inuit populations, oral cancer is found to be 25–40 times more frequent than in
non-Inuit populations in the USA, Canada and Denmark.86 This malignancy accounts for 4–7%
of all malignancies in Inuit as opposed to less than 0.1% in non-Inuit populations in USA, Can-
ada and Denmark.86 In Nunavut, oral cancer accounted for 6% of all cancers affecting Nu-
navummiut between 1999 and 2011.
What are the risk factors?
Research suggests that there are overlapping risk factors in oral cancer development: (1) genetics, (2) environment including
toxins like tobacco, alcohol and dietary items and (3) infectious agents like EBV and HPV. These factors can act independently or
synergistically: it was noted that HPV increased risk 2-fold, smoking increased risk 5.8-fold, and HPV plus smoking increased risk
15-fold.95 Differentiated and undifferentiated tumor types are also distinctly influenced by these risk factors.
Oral cancer tumors fall into two major categories: (1) differentiated and (2) undifferentiated. Differentiated tumors are strongly
associated with tobacco use, and risk was found to increase according to duration and frequency of use. Undifferentiated tumors
are strongly associated with viral infection accounting for a 2-4-fold increase in risk.8, 42, 87 In high incidence areas generally undif-
ferentiated nasopharyngeal cancer dominates.8, 42 Further examination is required to determine the dominant tumor grade in
Nunavut.
1. Genetics — Inuit generally retain their risk of oral cancer even after decades of migrating to low prevalence areas,
indicating involvement of genetic factors or early life environmental factors that influence risk.8 Genetic predisposi-
tion is supported by reports of familial clustering with an 8-fold [4.1-14.0] increase in risk experienced by first degree
relatives of Inuit with nasopharyngeal carcinoma.43
Environmental Factors — Presently, 60% of Nunavummiut 12 years or older report
smoking, which is three times higher than the national average.88 In one study, heavy
tobacco and alcohol use accounted for 57% [16–98%] of differentiated tumors.87 It has
also been found that ingesting preserved foods during childhood that contain nitrosa-
mines like Chinese salt-preserved fish, preserved meat and vegetables from North Africa
and traditional Inuit dried fish increases risk of oral cancer later in life.22, 42
Infectious Agents — Worldwide, infection is estimated to contribute 25.6% to oropharyngeal cancer risk and 85.5%
to nasopharyngeal cancer risk.36 Both EBV and HPV have been implicated in oral cancer. EBV is a well-established risk
factor, especially with childhood infection, and evidence is mounting for HPV.8, 42, 45, 87
Inuit children have a distinct pattern of EBV acquisition characterized by early primary infection and high antibody
titres, increasing their risk for oral cancer later in life.82 HPV presence in the oral cavity is associated with a 3.7-fold
[1.5-9.3] increased risk of oral cancer, independent of alcohol and tobacco exposure.99 It is possible that the distinct
pattern of infectious agents in Nunavut contribute to higher oral cancer rates.
2.
3.
Cancer in Nunavut: 1999-2011 15
What are oral cancer rates in Nunavut and how do we compare to the rest of Canada?
Are there regional differences in oral cancer rates across Nunavut?
Of all the regions, Kitikmeot had the highest rate (12.7 cases
per 100,000) followed by Kivalliq (11.7 cases per 100,000)
and then Baffin (11.3 cases per 100,000).
However, if one looks at the number of cases, Baffin had the
highest proportion of cases (52%) followed by Kivalliq (28%)
then Kitikmeot (20%).
This means that while the rate is highest in the Kitikmeot
region, there is a greater number of people affected by oral
cancer in the Baffin region.
In Nunavut, there were 46
cases (26 female, 20 male)
diagnosed between 1999 and
2011.
Overall, the Nunavut ASIR has
slightly increased over time
and as of 2011 it was three
times higher than the nation-
al rate.
Are there age-related trends in oral cancer incidence in Nunavut?
In Nunavut, the average age at
diagnosis was 52.1 years, alt-
hough age ranged between 12
and 75 years (standard devia-
tion 15.0 years).
Nunavut Baffin Kivalliq Kitikmeot
Incidence Rate 11.65 11.30 11.65 12.73
0
2
4
6
8
10
12
14
Rat
e pe
r 10
0,00
0
Figure 14. Oral Cancer Average Incidence Rate per 100,000 by Region, 1999-2011
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut* 20.10 20.35 20.13 25.00 18.91 27.62 22.94 22.80 21.65 24.35 24.49
Canada** 9.00 8.80 8.60 8.60 8.80 8.20 9.10 8.65 8.84 8.68 8.69
0
5
10
15
20
25
30
Ra
te p
er
10
0,0
00
Figure 13. Oral Cancer, Age Standardized Incidence Rate per 100,000 for Canada and Nunavut, 2001-2011 105
* 3-year moving average.**Data CANSIM table 103-0553. 2008 data onward are estimates from personal communications with Public Health Agency of Canada.
10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
Incident Rate 2.32 0.00 0.00 8.91 6.29 10.46 24.77 25.15 35.44 24.06 50.44 145.7 187.0 64.23 0.00 0.00
0
20
40
60
80
100
120
140
160
180
200
Rat
e p
er 1
00,0
00
Figure 15. Oral Cancer Incidence Rate per 100,000 by Age Group, Nunavut, 1999-2011
16
Are there gender-related trends or differences in oral cancer rates in Nunavut?
While Nunavut rates by gender do not significantly differ over time, the female rate generally exceeded the male rate up until
2009. Looking at the national picture, the male rate is consistently higher than the female rate and this difference is significant.
What mortality data are available for oral cancer?
Death clearance data are obtained from Statistics Canada and are available for years 1999-2008. For Nunavummiut diagnosed
with oral cancer, 9% died within one year of diagnosis.
Discussion: What does this information mean for Nunavummiut?
Overall, oral cancer rates are significantly higher in Nunavut as compared to the national average and are trending up. Factors in-
fluencing this dynamic and potentially affecting cancer risk are diverse and interrelated with genetics, environmental factors and
infectious agents. While it is not possible to change genetic risk, strategic increases in screening targeting individuals who have a
family history of disease can potentially assist with early detection and improve prognosis.
Behaviour modification is also essential to reducing oral cancer rates. Smoking is a major modifiable risk factor; continued efforts
with the Nunavut Tobacco Reduction Strategy are essential to reducing risk. Prevention and control of communicable diseases are
also important in risk reduction (e.g. HPV immunization).
Further work in Nunavut is necessary to determine the tumor grade in order to better tailor risk reduction strategies.
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut Female* 26.23 45.28 41.70 43.73 18.10 28.99 30.65 34.67 21.31 16.47 12.16
Nunavut Male* 14.38 2.89 5.48 12.82 19.52 26.43 16.19 13.51 22.75 32.16 35.00
Canada Female** 5.00 5.40 5.20 5.10 5.20 5.30 5.60 5.00 5.00 5.00 5.00
Canada Male** 12.70 12.50 12.60 12.80 12.60 11.80 13.10 12.00 11.00 11.00 11.00
0
5
10
15
20
25
30
35
40
45
50
Rat
e p
er
10
0,0
00
Figure 16. Oral Cancer, Age-Standardized Incidence Rate per 100,000 for Canada and Nunavut by gender, 2001-201112-15, 105
* 3-year moving average used**Data from CANSIM table 103-0553, with the exception of 2008-2011 data which are estimates obtained from Annual Canadian Cancer Society Reports.
Cancer in Nunavut: 1999-2011 17
Esophageal cancer accounted for 1% (10 male) of cancers between 1999 and 2011, averaging 1 case per year with a median
diagnosis age of 70 years (range 42-77, standard deviation 12.47 years). In Nunavut, 70% of the identified cases were adenocarci-
nomas. Nunavut's rate fluctuates but generally exceeds the national rate; in 2011 it was three times higher than the national rate.
For Nunavummiut diagnosed with esophageal
cancer, 33% died within one year of diagnosis.
Incidence and etiology of esophageal cancer
varies by histology.56 The primary determinants
of adenocarcinoma are: (1) gastro-esophageal
reflux disease, (2) high BMI and (3) tobacco use
but it is affected to a lesser degree than squa-
mous-cell carcinoma (SCC).56 SCC is primarily
affected by tobacco and alcohol use; there is
evidence that family history impacts both histo-
logical types.56, 114, 115 There is consistent evi-
dence that diet impacts esophageal cancer risk,
with fruits and vegetables reducing risk.56, 115
Stomach cancer accounted for 3% (8 female, 15 male) of cancers between 1999 and 2011, averaging 2 cases per year with an
average age at diagnosis of 59.9 years (range 30-92, standard deviation 16.7 years). Stomach cancer etiology differs by topogra-
phy.114 Of the 23 cases: 17% were cardia, 39% were non-cardia and 43% were unspecified topography. Nunavut rates increased
between 2001 and 2005 then trend down. For Nunavummiut diagnosed with stomach cancer, 55% died within one year of diagno-
sis.
Statistical modeling suggests the contribution of
risk factors to stomach cancer development is:
28% genes, 10% shared environmental factors
and 62% environmental factors.63
Worldwide, the population attributable fraction
of infectious agents in non-cardia gastric carci-
noma is 74.7% with H. pylori most strongly as-
sociated.36 In Nunavut, 50 to 60% of adults test-
ed positive for H. pylori exposure.39, 80 Over-
crowding, number of siblings and narrow age
gap between siblings independently increase
risk of acquiring H. pylori infection.65
Other factors consistently associated with increased risk of stomach cancer are: (1) peptic ulcers and chronic gastritis, although
both are associated with H. pylori infection, (2) ionizing radiation, (3) pernicious anemia and (4) nitrosamine compounds found in
preserved meats.63 Fruit and vegetable consumption, independent of other dietary factors, reduces stomach cancer risk.63
Digestive System:
Esophagus, Stomach, Liver, Pancreas, Other Gastrointestinal
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut* 15.95 11.41 7.45 8.81 13.37 5.92 4.56 0.00 4.88 7.93 11.78
Canada** 3.6 3.7 3.8 3.7 3.8 3.7 3.8 3.9 4.0 3.9 4.0
0
2
4
6
8
10
12
14
16
18
Rat
e p
er 1
00,0
00
Figure 17. Esophagus Cancer Age-Standardized Incidence Rate per 100,000 for Nunavut and Canada, 2001-2011105
* 3-year moving average.**Data CANSIM table 103-0553. 2008 data onward are estimates from personal communications with Public Health Agency of Canada.
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut* 13.38 20.99 28.71 32.69 32.96 23.21 28.38 22.04 22.04 5.88 1.29
Canada** 8.2 7.8 7.8 7.9 7.7 7.5 7.3 7.3 7.2 6.8 7.0
0
5
10
15
20
25
30
35
Ra
te p
er
10
0,0
00
Figure 18. Stomach Cancer Age-Standardized Incidence Rate per 100,000 for Nunavut and Canada, 2001-2011105
* 3-year moving average.**Data CANSIM table 103-0553. 2008 data onward are estimates from personal communications with Public Health Agency of Canada.
18
Liver cancer accounted for 1% (2 female, 4 male) of all cancers between 1999 and 2011, averaging 0.5 cases per year. The aver-
age age at diagnosis was 62.2 years (range 49-78, standard deviation 12.2 years). The Nunavut gender ratio is consistent with liter-
ature where the male rate is 2-4 times higher than the female rate.85 There are too few cases to trend; however, this cancer is on
the rise in the Canadian population, an increase attributed to increasing viral hepatitis rates.35, 116
Viral hepatitis plays a major role in the develop-
ment of primary liver cancer, with chronic infec-
tion being associated with 80% of incident cases
globally.94
The percentage of liver cancer cases in devel-
oped countries attributable to Hepatitis B infec-
tion is 23% and for Hepatitis C is 20%.85 In the
Canadian Arctic the prevalence of Hepatitis B is
about 5% and Hepatitis C is between 1-18%.83
Other recognized liver cancer risk factors in-
clude: (1) Afloatoxin, a group of mycotoxins
found in improperly stored foods, (2) alcohol
consumption, with 25 g/day increasing risk 1.2-
fold [1.1-1.3] and with 100g/day further increasing risk to 1.8-fold [1.5-2.2].25, 32 Alcohol works synergistically with cirrhosis and
Hepatitis C to significantly increase risk, (3) tobacco use, which increases risk 1.6-fold [1.3-1.9], (4) obesity (BMI ≥ 30), which in-
creases risk 1.9-fold [1.5-2.4] and (5) diabetes, which is an independent factor.25, 44, 71
Pancreatic cancer accounted for 2% of all cancers (11 female, 7 male) between 1999 and 2011, averaging 1 case per year with a
median age at diagnosis of 65 years (range 6-77, standard deviation 19.8 years). Pancreatic cancer in Nunavut was briefly lower
than the national rate between 2005 and 2008,
but generally exceeds the national rate.
For Nunavummiut diagnosed with pancreatic
cancer, 88% died within one year of diagnosis.
This high mortality rate is consistent with litera-
ture.16, 72
Factors contributing to the development of
pancreatic cancer are not well understood;
however, tobacco use is a well established risk
factor increasing risk 1.7-fold [1.5-1.9].44
Other factors associated with disease risk are:
(1) family history of disease (found in 5-10% of
cases), (2) particular genetic alterations (e.g.
BRCA2), (3) long-standing history of type II diabetes (5-10 years), which increases chances of disease 1.5-fold [1.3-1.8], (4) chronic
pancreatitis and (5) diet.57, 75, 98
Other gastrointestinal cancers accounted for 3% of all cancer cases (12 female, 8 male) between 1999 and 2011, averaging 2
cases per year.
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut* 11.41 11.41 0.00 0.00 0.00 7.31 7.31 7.31 0.00 0.97 2.02
Canada** 3.3 3.3 3.2 3.3 3.6 3.7 3.8 3.8 4.0 3.9 4.1
0
2
4
6
8
10
12
Ra
te p
er
10
0,0
00
Figure 19. Liver Cancer Age-Standardized Incident Rate per 100,000 for Nunavut and Canada, 2001-2011105
* 3-year moving average.**Data CANSIM table 103-0553. 2008 data onward are estimates from personal communications with Public Health Agency of Canada.
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut* 13.39 21.89 29.34 17.67 8.96 1.51 1.51 0.00 13.84 19.79 23.05
Canada** 9.3 9.1 9.4 9.5 9.6 9 9.4 9.5 9.6 9.0 9.4
0
5
10
15
20
25
30
35
Rat
e p
er 1
00,0
00
Figure 20. Pancreas Cancer Age-Standardized Incidence Rate per 100,000 for Nunavut and Canada, 2001-2011105
* 3-year moving average.**Data CANSIM table 103-0553. 2008 data onward are estimates from personal communications with Public Health Agency of Canada.
Cancer in Nunavut: 1999-2011 19
Urinary System:
Bladder and Kidney Bladder cancer accounted for 1% of cancers
(2 female, 5 male) between 1999 and 2011,
averaging 0.5 cases per year with a median di-
agnosis age of 44 years (range 2-68, standard
deviation 25.3 years).
Nunavut rates appear to be trending up but still
remain a fraction of the national rate. This is
consistent with findings throughout the circum-
polar region that bladder cancer is rare among
Inuit.8
Risk factors include: (1) smoking (associated
with a 2.8-fold [2.2-3.5] risk increase (including
renal pelvis)), (2) exposure to chemical com-
pounds (e.g. benzidine, beta-naphthylamine, polycyclic aromatic hydrocarbons, diesel exhaust), (3) infectious diseases (e.g. Schis-
tosoma haemarobium, HPV) and (4) hereditary factors, which are thought to contribute 7% to risk.34, 44, 76, 92
Kidney cancer accounted for 4% of all cancer cases (14 female, 15 male) between 1999 and 2011, averaging 2 cases per year
with a median diagnosis age of 62 years (range 1-76, standard deviation 19.3 years). Kidney cancer in Nunavut was briefly lower
than the national rate in 2006 and 2007, but otherwise exceeds the national rate.
Lifestyle factors consistently associated with
risk include smoking and obesity. Smoking is
associated with a 1.5-fold [1.3-1.7] risk in-
crease (excluding renal pelvis).44
Obesity is estimated to account for 31-43% of
renal cancers in the United States and Eu-
rope.11 For overweight or obese individuals, it
is estimated that for every 5kg/m2 weight in-
crease there is a risk increase of 24% for men
and 34% for women.91
Other risk factors include: (1) hypertension, (2)
industrial agents such as trichloroethylene
(used as a metal degreaser and chemical addi-
tive) and (3) hereditary factors, which are thought to contribute 7% to risk; this is further supported by the increased risk seen in
those with first degree relatives diagnosed with kidney cancer.24, 28, 34
There is inconsistent evidence around the risk associated with cadmium, uranium, arsenic, nitrate and radon.24 Protective factors
include diets rich in fruits and vegetables.24
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut* 0.00 0.00 0.00 0.66 2.17 2.17 2.20 1.90 1.90 3.87 4.28
Canada** 16.4 16.5 16.9 16.9 16.5 16.5 16.3 16.4 16.8 16.5 16.3
0
2
4
6
8
10
12
14
16
18
Ra
te p
er
10
0,0
00
Figure 21. Bladder Cancer Age-Standardized Incidence Rate per 100,000 for Nunavut and Canada, 2001-2011105
* 3-year moving average.**Data CANSIM table 103-0553. 2008 data onward are estimates from personal communications with Public Health Agency of Canada.
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut* 9.58 20.71 29.38 27.84 17.32 8.07 8.07 13.41 21.12 22.35 20.39
Canada** 10.5 10.5 10.4 10.6 10.8 11.2 11.9 11.5 11.6 11.5 12.2
0
5
10
15
20
25
30
35
Ra
te p
er
10
0,0
00
Figure 22. Kidney Cancer Age-Standardized Incidence Rate per 100,000 for Nunavut and Canada, 2001-2011105
* 3-year moving average.**Data CANSIM table 103-0553. 2008 data onward are estimates from personal communications with Public Health Agency of Canada.
20
Gynecological Cancers:
Breast, Cervix, Ovary, Uterus (Body), Other
Quick facts: Cervix
Average of 1 case per year
Average age at diagnosis 43 years
8% mortality within one year of diagnosis
Quick facts: Breast
Average of 5 cases per year
Average age at diagnosis 53 years
8% mortality within one year of diagnosis
Genetics — There are multiple genes implicated in gynecological cancers. For example, the BRCA1 and BRCA2
genes play a role in DNA repair.101 With mutation of these genes, the cumulative risk by age 70 for breast cancer is
55% [50-59%] for BRCA1 and 47% [42-51%] for BRCA2.23 For ovarian cancer, the cumulative risk is 39% [34-45%] for
BRCA1 and 17% [13-21%] for BRCA2.23 Genetic factors are thought to contribute 27% to breast cancer risk and 22%
to cervical cancer risk.34
Hormones — Estrogen levels are increased in ovulating women thus any factor influencing ovulation decreases
breast, ovarian and uterine cancer risk including: (1) pregnancy (high frequency and young age at first birth), (2) later
age of menarche, (3) early onset of menopause and (4) removal of ovaries.3, 60, 84
Oral contraceptives also influence risk of gynecological cancers, providing a strong protective effect for ovarian can-
cer (reducing risk 0.50-fold [0.33-0.75]) and also a protective effect for uterine cancer.3, 60, 84 The affect of contracep-
tives on breast cancer is weak with suggestions that older, high-hormone formulas actually increase risk, a risk which
is mitigated in newer, low-dose formulas.60
Lifestyle — With a trend towards adopting a westernized lifestyle, gynecological cancer risk has been increasing in
circumpolar women due to: (1) decreased birth rate, (2) increased mean maternal age at first birth and (3) pattern of
breast feeding (e.g. decreased duration).42, 74, 84 Alcohol also plays a dose-dependent role, increasing breast cancer
risk 1.3-fold [1.2-1.3] with 25g/day and 2.4-fold [2.1-2.8] with 100g/day.32 Smoking is associated with a 1.8-fold [1.5-
2.2] increase in cervical cancer.44 Uterine cancer risk is associated with: (1) obesity (2-3-fold increase in risk), (2) phys-
ical inactivity and (3) diabetes.3
Infectious Agents — Globally, an estimated 70% of invasive cervical cancer cases were associated with either
HPV16 or 18, with an additional 18% of cases attributable to HPV strains 31, 33, 35, 45, 52 and 58.99 The prevalence
of oncogenic HPV types (16 and 18) in one Nunavut study was 25.8% [23.8-27.9].52
Nunavut offers a publically funded HPV vaccination program to girls in grade 6 (≥ 9 years). Presently, Gardasil is used
which protects against HPV types 6, 11, 16 and 18 and is found to be 99% effective in girls aged 16-26 years with se-
ries completion.89 Presently, territorial HPV coverage rates are not available.
Gynecological cancers account for 10-15% of all cancers globally and in Nunavut, they account
for 12%.1 Traditionally, Inuit experience lower rates of gynecological cancers than their non-Inuit
counterparts, although with changing lifestyles this trend is changing.42
What are the risk factors for gynecological cancers?
Gynecological cancers are differentially affected by risk factors including: genetics, hormones, life-
style and infectious agents. In considering breast cancer risk, it is important to recognize that
breast cancer is not a single disease but a molecularly distinct group of cancers.101 Each group has
a distinct etiology and pathology due to differences in: (1) estrogen-receptor positivity, (2) progesterone-receptor positivity
and (3) HER2 status and as such are differentially affected by risk factors.101
1.
2.
3.
4.
Cancer in Nunavut: 1999-2011 21
Breast cancer is the leading cancer type
amongst female Nunavummiut and accounts
for 8% (63 cases) of all cancer cases diagnosed
between 1999 and 2011 (excluding 1 male).
The average age at diagnosis is 53.4 years
(range 25-77, standard deviation 11.3 years).
The rate is below the national and Northwest
territories (NWT) rates; this difference is not
significant.
Cervical cancer accounts for 2% (16 cases)
of all cancer cases diagnosed between 1999
and 2011. The average age at diagnosis is 42.8
years (range 26-60, standard deviation 9.2
years). The rate exceeds the Canadian rate, but
not significantly.
Ovarian cancer accounts for 1% (7 cases) of all
cancer cases diagnosed between 1999 and 2011,
averaging 0.5 cases per year. The median age at
diagnosis was 58 years (range 23-72, standard devi-
ation 17.1 years). The ASIR is generally 1.2 times
lower than Canada.
Uterus (Body) cancer accounts for 0.6% (5 cas-
es) of all cases diagnosed between 1999 and 2011.
The median age at diagnosis was 46 years (range 28
-50, standard deviation 9.3 years). There are too
few cases to trend; however, the ASIR is consistent-
ly lower than Canada.
Other gynecological cancers accounted for
1% of all cancers (8 cases) between 1999 and 2011.
What are Nunavut gynecological cancer rates and how do we compare to Canada?
Are there regional differences in female reproductive cancer rates across Nunavut?
Baffin had the highest breast cancer rate (92.2 cases per
100,000) followed by Kitikmeot (44.5 cases per 100,000) and
then Kivalliq (34.0 cases per 100,000). Baffin had the highest
proportion of cases (47%) followed by Kivalliq (28%) and Ki-
tikmeot (25%).
Baffin had the highest cervical cancer rate (21.7 cases per
100,000) followed by the Kitikmeot (8.5 cases per 100,000).
Baffin had the highest proportion of cases (81%) with the rest of
cases in Kitikmeot (19%). Nunavut Baffin Kivalliq Kitikmeot
Breast 33.59 92.16 34.03 44.47
Cervix 8.30 21.67 0.00 8.47
0102030405060708090
100
Rat
e p
er
10
0,0
00
Figure 25. Breast and Cervical Cancer Average Incidence Rate per 100,000 by Region, 1999-2011
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut* 3.70 6.15 8.09 10.65 10.98 8.05 18.17 20.68 20.31 10.15 7.06
NWT** 0.00
Canada^ 8.20 8.00 7.80 7.70 7.30 7.50 7.80 7.37 7.89 7.43 7.47
0
5
10
15
20
25
Ra
te p
er
10
0,0
00
Figure 24. Cervical Cancer, Age-Standardized Incidence Rate per 100,000 for Canada, Nunavut, and Northwest Territories, 2001-2011105
* 3-year moving average.**Data from CANSIM table 103-0553. Blank cells indicate unavailable data.^ Data CANSIM table 103-0553. 2008 data onward are estimates from personal communications with Public Health Agency of Canada.
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut* 55.57 59.10 24.23 32.13 64.51 91.71 96.18 76.91 62.58 64.38 59.92
NWT** 129.70 95.60 206.20 84.80 79.90 85.10 100.00 81.70 109.00
Canada^ 100.40 102.40 96.90 97.20 98.50 98.30 98.30 97.05 99.08 101.07 98.77
0
50
100
150
200
250
Ra
te p
er
10
0,0
00
Figure 23. Breast Cancer in Females, Age-Standardized Incidence Rate per 100,000 for Canada, Nunavut, and Northwest Territories, 2001-2011105
* 3-year moving average.**Data from CANSIM table 103-0553. Blank cells indicate unavailable data.^ Data CANSIM table 103-0553. 2008 data onward are estimates from personal communications with Public Health Agency of Canada.
22
Are there age-related trends in female reproductive cancer incidence in Nunavut?
Age-related trends for gynecological cancers in Nunavut cannot be established due to low case counts and sporadic incidence.
For gynecological cancers in Canada, 30% of cases were younger than 50 years and 46% were between 50 and 70 years.1 The ex-
ception to this distribution is cervical cancers where the majority (58%) of cases were under 50 years.1 Given that the majority of
Nunavut’s population is under 50 years, this has implications for both breast and cervical cancer screening.
What mortality data are available for female reproductive cancer? Death clearance data are obtained from Statistics Canada and are available for years 1999-2008. For Nunavummiut diagnosed with:
Breast cancer: 8% died within one year of diagnosis.
Cervical cancer: 8% died within one year of diagnosis.
Discussion: What does this information mean for Nunavummiut?
Nunavut offers a Well-Woman clinic that includes screening for gynecological cancers. The 2011 Nunavut Well-Woman guidelines
recommend cervical screening annually until three normal results are established, then every two to three years for all sexually
active women ending at age 70 if recent tests were normal. The Well-Woman clinics include a clinical breast exam and guidelines
recommend mammography every 1-2 years for low-risk women aged 50 to 69 (for women with a family history, screening should
start 5-years prior to the age of the diagnosed relative). It is ideal that Well-Woman clinics combine reproductive care and cancer
screening as a study in Nunavik found cervical screening to be related to accessing healthcare for reproductive care and family
planning.21
One systematic review found that in a follow-up of invasive cervical cancer cases, 54% [46-66%] of the women had a history of nev-
er being screened or being inadequately screened.102 This quantifies the potential to improve early detection and thus improve the
prognosis for cervical cancer through screening. In Canada (excluding territories, Quebec, Prince Edward Island), when controlled
for hysterectomy, 74% of women age 20 to 69 had been screened at least once between 2006 and 2008.17 Based on these data,
cervical cancer screening can likely be improved in Nunavut and meaningfully impact case detection.
Cervical and breast cancer screening are essential to early detection and improving prognosis. Presently, cervical screening guide-
lines are being revised and mammography guidelines are not followed due to logistical difficulties of screening in remote commu-
nities. HPV vaccination promotion and sexual health messaging are paramount to lowering cervical cancer rates. In addition, fur-
ther investigation into tumor grade for breast cancer in order to identify specific breast cancer groups may provide insight to tailor
prevention and screening programs.101
25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
Breast 5.94 0.00 10.46 28.90 85.51 41.34 56.13 138.70 41.63 187.06 128.45 0.00 0.00
Cervix 2.97 6.29 10.46 16.52 5.03 17.72 8.02 12.61 0.00 0.00 0.00 0.00 0.00
0
20
40
60
80
100
120
140
160
180
200
Rate
per
100,0
00
Figure 26. Breast and Cervical Cancer Incidence Rate per 100,000 by Age Group, Nunavut, 1999-2011
Cancer in Nunavut: 1999-2011 23
Prostate cancer is the third leading cancer site amongst male Nunavummiut and accounts for 3% of all cancer cases (24 cases)
diagnosed between 1999 and 2011. The Nunavut rate is significantly below the national average with the exception of 2003 and
2004. This finding is consistent with other circumpolar regions.8, 37, 42
There are likely both genetic and
lifestyle factors that impact pros-
tate cancer risk. This assertion is
supported by the finding that Inuit
who emigrate are at increased risk
for prostate cancer but their risk
remains 70% lower than the desti-
nation country.8
Non-modifiable factors thought to
be related to risk are: (1) genetics
(e.g. lower androgen receptor ac-
tivity, which is protective) and (2)
increasing age, which increases
risk.46, 93
Modifiable factors thought to be
related to risk are: (1) diet (traditional diets high in omega-3 fatty acids are protective and high-calorie diets increase risk), (2) obe-
sity, which increases risk and (3) physical activity, which is protective.42, 112
Testicular cancer accounts for 0.7% of all cancers (5 cases) diagnosed between 1999 and 2011. There are too few cases to
trend; however, the rate is generally 2 to 5 times lower than the national rate. In recent years, this trend seems to be changing
with the 2010 rate being almost equal to the national rate and the 2011 rate being 1.6 times higher than the national rate.
Testicular cancer risk factors are not well understood but it has been noted to predominantly occur in those of European ancestry
and is most consistently associated with failure of the testicles to descend (4.3-fold [3.6-5.1]), prior testicular cancer history and
family history of disease.26, 31
Other male cancer accounted for 0.4% of all cancers (3 cases) diagnosed between 1999 and 2011.
Male Reproductive Cancers:
Prostate, Testis, Other
What are male reproductive cancer rates in Nunavut and how do we compare to the rest of Canada?
Quick facts: Prostate
3rd leading cancer site in men
Average of 2 cases per year
Average age at diagnosis 65 years
0% mortality within one year of diagnosis
Nunavut male reproductive cancer rates have historically been lower than the national average, but with changing lifestyles this
trend is changing.20, 42
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut* 0.00 27.67 63.16 65.77 38.10 18.39 18.41 34.37 29.58 40.73 34.06
NWT** 86.50 154.20 102.80
Canada^ 133.20 123.80 120.40 122.60 121.90 126.10 125.00 113.77 111.21 107.62 107.35
0
20
40
60
80
100
120
140
160
180
Rat
e p
er
10
0,0
00
Figure 27. Prostate Cancer, Age-Standardized Incidence Rate per 100,000 for Canada, Nunavut, and Northwest Territories, 2001-2011105
* 3-year moving average.**Data from CANSIM table 103-0553. Blank cells indicate unavailable data.^ Data CANSIM table 103-0553. 2008 data onward are estimates from personal communications with Public Health Agency of Canada.
24
Are there regional differences in male reproductive cancer rates across Nunavut?
Are there age-related trends in male reproductive cancer incidence in Nunavut?
Baffin had the highest prostate cancer rate (14.1 cases per
100,000) followed by Kivalliq (8.9 cases per 100,000) and then
Kitikmeot (8.3 per 100,000). Baffin had the highest proportion of
cases (67%) followed by Kivalliq (21%) and Kitikmeot (12%).
There are too few testicular cancer cases to regionally trend.
Prostate cancer incidence gener-
ally trends up by age group,
sharply declining after 80-84
years.
Testicular cancer cases are clus-
tered between 28 and 34 years.
What mortality data are available for prostate cancer?
Death clearance data are obtained from Statistics Canada and are available for years 1999-2008. For Nunavummiut diagnosed
with prostate cancer, 0% died within one year of diagnosis.
Discussion: What does this information mean for Nunavummiut?
A reversal of the trend of lower prostate cancer incidence has been noted in Alaskan Inuit and is thought to be attributable to the
adoption of a western lifestyle.69, 100 As high-calorie diets, obesity, and low physical activity become more common and there is an
increase in life expectancy, it is anticipated that there may be a corresponding increase in prostate cancer incidence in the coming
decades.20, 42, 93 Healthy lifestyles and screening are essential to reducing male reproductive cancer risk and improving prognosis.
Nunavut Baffin Kivalliq Kitikmeot
Incidence Rate 11.57 14.10 8.86 8.25
0
2
4
6
8
10
12
14
16
Rat
e p
er 1
00,0
00
Figure 28. Prostate Cancer Average Incidence Rate per 100,000 by Region, 1999-2011
45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
Incidence Rate 5.03 0.00 64.15 75.65 41.63 112.23 128.45 266.67 0.00
0
50
100
150
200
250
300
Ra
te p
er
100
,00
0
Figure 29. Prostate Cancer Incidence Rate per 100,000 by Age Group, Nunavut, 1999-2011
Cancer in Nunavut: 1999-2011 25
Hematopoietic & Lymph node Cancers:
Hodgkin Lymphoma, Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, Other Lymph
Hematopoietic cancers remain lower in Nunavut than nationally. Risk factors differ by cancer type and subgroupings within
each type.
There are no clear, overarching lifestyle or dietary risk factors for leukemia and lymphoma; risk differs by subgroupings. Smoking
has been consistently associated with Hodgkin lymphoma; its effects on other lymphomas is unclear.61 Chemical exposure and radi-
ation exposure in childhood are associated with leukemia.64, 119
Infectious diseases are also associated: (1) EBV is implicated in Hodgkin and non-Hodgkin lymphoma, (2) H. pylori is implicated in B-
cell lymphomas in mucosa-associated lymph tissue, increasing risk 7.2-fold (3) Chlamydia psittaci in eye tissues are linked to B-cell
lymphomas in this area, (4) Campylobacter jejuni is linked with B-cell lymphomas in the small intestine, (5) HTLV-1 is implicated in
Adult T-cell leukemia and lymphoma, and (6) Hepatitis C is associated with non-Hodgkin lymphoma.30, 36, 77, 94
Hodgkin Lymphoma accounted for 2 cases (2 male) between 1999 and 2011 which was 0.3% of all cancer cases and averages
0.2 cases per year. This sample size is too small to provide a meaningful epidemiologic description.
Leukemia accounted for 12 cases (6 female,
6 male) between 1999 and 2011 which was 2%
of all cancer cases and averages one case per
year. The median age at diagnosis was 31.5
years (range 1-67, standard deviation 25.9
years).
Multiple Myeloma has accounted for a
single case between 1999 and 2011 which was
0.1% of all cancer cases and averages 0.1 cases
per year. This sample size is too small to pro-
vide a meaningful epidemiologic description.
Non-Hodgkin Lymphoma accounted for 7
cases (3 female, 4 male) between 1999 and
2011 which was 1% of all cancer cases and aver-
ages 0.5 cases per year. The average age at diag-
nosis was 60.7 years (range 50 -72, standard
deviation 8.8).
Other lymph cancers accounted for 1 case
between 1999 and 2011.
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut* 1.46 1.46 3.97 3.97 8.52 7.20 7.20 2.65 3.85 3.85 5.00
Canada** 15.9 16 16.1 16.8 16.7 16.8 16.9 16.6 16.5 16.6 16.8
0
2
4
6
8
10
12
14
16
18
Rat
e p
er
10
0,0
00
Figure 31. Non-Hodgkin Lymphoma Cancer, Age Standardized Incidence Rate per 100,000 for Canada and Nunavut, 2001-2011105
* 3-year moving average.**Data CANSIM table 103-0553. 2008 data onward are estimates from personal communications with Public Health Agency of Canada.
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut* 0.93 0.00 0.66 2.24 5.49 6.79 8.57 9.44 8.12 4.75 0.64
Canada** 11.1 11.6 11.9 11.7 11.8 11.9 12.2 12.1 12.1 12.2 12.5
0
2
4
6
8
10
12
14
Rat
e p
er 1
00,0
00
Figure 30. Leukemia Cancer, Age Standardized Incidence Rate per 100,000 for Canada and Nunavut, 2001-2011105
* 3-year moving average.**Data CANSIM table 103-0553. 2008 data onward are estimates from personal communications with Public Health Agency of Canada.
26
Thyroid and Other Endocrine
Thyroid cancer accounted for 1% of all cases (9 female,
2 male) between 1999 and 2011, averaging one case per
year. The average age at diagnosis was 42.3 years (range 22
-66, standard deviation 14.8 years). The Canadian thyroid
cancer rate is trending up especially in women. This is re-
flected globally and is not entirely explained by a change in
diagnostic techniques.40 Since 2003, the Nunavut rate has
been 4-12 times below the national rate.
Histology and grade are both important considerations for
risk factors. Follicular tumors are more common than papil-
lary tumors in regions of iodine insufficiency and differenti-
ated carcinoma are most frequently diagnosed in women.97 In Nunavut, all cases were papillary tumors and grade was unavailable.
Exposure to ionizing radiation in childhood and a history of thyroid abnormalities are the only widely-recognized risk factors for
thyroid cancer.53, 64, 81, 97
Other endocrine cancers accounted for 2 cases (2 female) between 1999 and 2011.
Brain
Brain cancer accounted for 2% of all cancer cases (10 fe-
male, 5 male) between 1999 and 2011. On average brain
cancer accounts for 1 case per year with a median diagnosis
age of 29 years (range 1-81 years, standard deviation 23.6
years).
Because of the small annual case counts, the Nunavut rate is
highly unstable. When the Nunavut brain cancer rate is av-
eraged over the 11-year period under study it does not differ
significantly from the national rate.
Connective & Soft Tissue Cancers:
Bone, Joint, Soft Tissue, Melanoma, Other Skin Bone and joint cancers accounted for 2 cases (1 female, 1 male) between 1999 and 2011. Soft tissue cancers accounted
for 2 cases (2 female) between 1999 and 2011. Melanoma accounted for 4 cases (1 female, 3 male) between 1999 and 2011.
Other skin cancers accounted for 6 cases (4 female, 2 male) between 1999 and 2011.
Unknown Unknown cancers accounted for 2% of all cancer cases (8 female, 9 male) diagnosed between 1999 and 2011.
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut* 11.89 11.89 4.07 1.37 1.37 2.30 2.16 2.16 1.23 1.10 3.20
Canada** 7.4 8.6 8.7 9.5 10.7 10.9 11.6 12.2 12.6 13.0 13.3
0
2
4
6
8
10
12
14
Rat
e p
er
10
0,0
00
Figure 32. Thyroid Cancer, Age Standardized Incidence Rate per 100,000 for Canada and Nunavut, 2001-2011105
* 3-year moving average.**Data CANSIM table 103-0553. 2008 data onward are estimates from personal communications with Public Health Agency of Canada.
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Nunavut* 7.94 6.23 3.75 10.36 12.68 12.68 3.54 0.00 0.00 1.29 4.16
Canada** 6.4 6.2 6.4 6 6.4 6.3 6.4 6.9 6.9 6.7 6.9
0
2
4
6
8
10
12
14
Rat
e p
er
10
0,0
00
Figure 33. Brain Cancer, Age Standardized Incidence Rate per 100,000 for Canada and Nunavut, 2001-2011105
* 3-year moving average.**Data CANSIM table 103-0553. 2008 data onward are estimates from personal communications with Public Health Agency of Canada.
Cancer in Nunavut: 1999-2011 27
Summary Cancer is the leading cause of mortality and significantly contributes to illness in Nunavut. Nunavut’s pattern of cancer is distinct
from the rest of Canada with a higher rate of lung, colorectal and oral cancers and lower rates of reproductive cancers. When look-
ing at all cancers combined, the overall cancer rate is higher among Nunavut women when compared to the national rate while
the rate in Nunavut men is a fraction of the national rate.
Nunavummiut have a different risk factor profile than Canada. Factors increasing cancer risk include: higher tobacco use rates,
lower physical activity, dietary patterns, crowded housing conditions, different patterns of infectious diseases and increasing
chronic disease rates. However, the Tobacco Reduction Strategy, federal and territorial nutrition programs, alcohol restriction and
public health immunization programs have likely reduced the risk of some cancers.
Further work is required to lower cancer rates and cancer mortality in Nunavut. Particular focus on prevention and early detection
is required for the top cancers affecting Nunavummiut. Programs already in place regarding tobacco reduction, nutrition and im-
munization are essential to reducing the cancer rate in Nunavummiut. Further programs for screening and healthcare accessibility
are required to enable early detection, thereby improving prognosis and enabling Nunavummiut to remain as close as possible to
their communities for screening and treatment.
Recommendations Timely, complete cancer surveillance data to guide policy:
Regular auditing of the Nunavut cancer registry
Regular reporting schedule
Timely risk factor surveillance data:
Implement surveillance program to collect data on risk factors identified in this report
Advocate for improved representativeness on Canadian Community Health Survey
Cancer prevention strategies:
Continue Tobacco Reduction Strategy
Continue alcohol regulation strategy
Continue Food Security Strategy
Reduce communicable disease transmission (including but not limited to: EBV, HPV, TB, H. pylori)
Targeted early detection strategies:
Continue to improve the quality of the cervical cancer screening program
Review the breast cancer screening program
Colorectal screening program
Obtain further histological grading and molecular information on select cancers to tailor prevention strategies.
28
References:
Akhtar-Danest N, Lytwyn A, Elit L. Fiver-year trends in
mortality indices among gynecological cancer patients in
Canada. Gynecological Oncology 2012;127:620-624.
Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest
2003;123:21S–49S.
Amant F, Moerman P, Neven P, Timmenman D, Van Lim-
bergen E, Vergote I. Endometrial cancer. Lancet
2005;366:491-505.
Azagba S, Asbridge M. The association between smoking
bans and nicotine dependence: A longitudinal analysis of
current smokers in Canada. Addictive Behaviours
2013;38:2817-2820.
Baglietto L, Jenkins MA, Severi G, Giles GG, Bishop DT,
Boyle P , Hopper JL. Measures of familial aggregation de-
pend on definition of family history: meta-analysis for
colorectal cancer. Journal of Clinical Epidemiology
2006;59:114-124.
Beauregard MA, Ell J, Pikor RK, Ham LJ (2012). Nunavut
Carving Stone Deposit Evaluation Program (2010-2013):
third year results. Source: http://nunavutgeoscience.ca/
Bossé Y, Postma DS, Sin DD, Lamontagne M, Couture C,
Gaudreault N et al. Molecular signature of smoking in
human lung tissues (2012). Cancer Research 2012;72
(15):3753-3763
Boysen T, Friborg J, Andersen A, Poulsen GN, Wohlfahrt J ,
Melbye M. The Inuit Cancer pattern—The influence of
migration. International Journal of Cancer 2008;122:2568
-2572.
Brenner DR, McLaughlin JR, Hung RJ. Previous lung dis-
eases and lung cancer risk: a systematic review and meta-
analysis. PLoS One 2011;6(3):17479-17479.
Butterworth AS, HJiggins JPT , Pharoah P. Relative and
absolute risk of colorectal cancer for individuals with a
family history: a meta-analysis. European Journal of Can-
cer 2006;42:216-227.
Calle EE , Kaaks R. Overweight, obesity and cancer: epide-
miological evidence and proposed mechanisms. Nature
Reveiws 2004;4:579-591.
Canadian Cancer Society’s Advisory Committee on Cancer
Statistics. Canadian Cancer Statistics 2008. Toronto, ON:
Canadian Cancer Society, 2008. Source: http://
www.cancer.ca/~/media/cancer.ca/CW/cancer%
20information/cancer%20101/Canadian%20cancer%
20statistics/Canadian-Cancer-Statistics-2008-EN.pdf
Canadian Cancer Society’s Advisory Committee on Cancer
Statistics. Canadian Cancer Statistics 2009. Toronto, ON:
Canadian Cancer Society, 2009. Source: http://
www.cancer.ca/~/media/cancer.ca/CW/cancer%
20information/cancer%20101/Canadian%20cancer%
20statistics/Canadian-Cancer-Statistics-2009-EN.pdf
Canadian Cancer Society’s Advisory Committee on Cancer
Statistics. Canadian Cancer Statistics 2010. Toronto, ON:
Canadian Cancer Society, 2010. Source: http://
www.cancer.ca/~/media/cancer.ca/CW/cancer%
20information/cancer%20101/Canadian%20cancer%
20statistics/Canadian-Cancer-Statistics-2010-EN.pdf
Canadian Cancer Society’s Advisory Committee on Cancer
Statistics. Canadian Cancer Statistics 2011. Toronto, ON:
Canadian Cancer Society, 2011. Source: http://
www.cancer.ca/~/media/cancer.ca/CW/cancer%
20information/cancer%20101/Canadian%20cancer%
20statistics/Canadian-Cancer-Statistics-2011-EN.pdf
Canadian Cancer Society’s Advisory Committee on Cancer
Statistics. Canadian Cancer Statistics 2013. Toronto, ON:
Canadian Cancer Society, 2013. Source: http://
www.cancer.ca/~/media/cancer.ca/CW/cancer%
20information/cancer%20101/Canadian%20cancer%
20statistics/Canadian-Cancer-Statistics-2013---English.pdf
Canadian Partnership Against Cancer. Cervical cancer
screening in Canada: Monitoring program performance
2006-2008. Toronto (Canada), 2011: Canadian Partner-
ship Against Cancer.
Canavan C, Abrams KR , Mayberry J. Meta-analysis: colo-
rectal and small bowel cancer risk in patients with Crohn’s
disease. Aliment Pharmacol Ther 2006;23:1097-1104.
Carpagnano GE, Koutelou A, Natalicchio MI, Martinelli D,
Ruggieri C, Di Taranto A, Antonetti R, Carpagnano F , Fos-
chino-Barbaro MP. HPV in exhaled breath condensate of
lung cancer patients. British Journal of Cancer
2011;105:1183-1190.
Carrière GM, Tjepkema M, Pennock J, Goedhuis N. Cancer
patterns in Inuit Nunangat: 1998-2007. Int J Circumpolar
Health 2012;71:18581.
Cerigo H, Coutlee F, Franco EL , Brassard P. Factors associ-
ated with cervical cancer screening uptake amoung Inuit
women in Nunavik, Quebec, Canada. BMC Public Health
2013;13:438.
Cancer in Nunavut: 1999-2011 29
Chang ET, Adami H. The enigmatic epidemiology of naso-
pharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev
2006;15:1765-17777.
Chen S , Parmigiani. Meta-analysis of BRCA1 and BRCA2
penetrance. J Clin Oncol 2007;25:1329-1333.
Chow W, Dong LM , Devesa SS. Epidemiology and risk
factors for kidney cancer. Nat Rev Urol 2010;7(5):245-
257.
Chuang S, La Vecchia C , Boffetta P. Liver cacner: Descrip-
tive epidemiology and risk factors other than HVB and
HCV infection. Cancer Letters 2009;286:9-14.
Chung CC, Kanetsky PA, Wang Z, Hildebrandt MAT, Koster
R, Skotheim RI et al. Meta-analysis identifies four new
loci associated with testicular germ cell tumor. Nature
Genetics 2013;45(6):680-686.
Circumpolar Inuit Cancer Review Working Group: Kelly J,
Lanier A, Santos M, Healey S, Louchini R, Friborg J, Young
K, Ng C. Cancer among the circumpolar Inuit, 1989-2003.
II. Patterns and trends. Int J Circumpolar Health 2008;67
(5):408-20.
Clague J, Lin J, Cassidy A, Matin S, Tannir NM, Tamboli P,
Wood CG, Wu X. Family history and risk of renal cell carci-
noma: results from a case-control study and systematic
meta-analysis. Cancer Epidemiol Bio markers Prev 2009;
18:801-807.
Clement-Duchene C, Vignaud J-M, Stoufflet A, et al. Char-
acteristics of never smoker lung cancer including environ-
mental and occupational risk factors. Lung Cancer
2010;67(2):144–50.
Cohen JI, Fauci AS, Varmus H , Nabel GJ. Epstein-Barr Vi-
rus: An important vaccine target for cancer prevention.
Science Translational Medicine 2011;3(107):1-3.
Cook MB, Akre O, Forman D, Madigan MP, Richiardi L ,
McGlynn KA. A systematic review and meta-analysis of
perinatal variables in relation to the risk of testicular
cancer—experiences of the son. International Journal of
Epidemiology 2010;39:1605-1618.
Corrao G, Bagnardi V, Zambon A , LaVecchia C. A meta-
analysis of alcohol consumption and the risk of 15 diseas-
es. Preventive Medicine 2004;38:613-619.
Courad S, Zalcman G, Milleron B, Morin F, Souquet. Lung
cancer in never smokers— A review. European Journal of
Cancer 2012;48:1299-1311.
Czene K, Lichtenstein P, Hemminki K. Environmental and
heritable causes of cancer among 9.6 million individuals
in the Swedish family-cancer database. Int J. Cancer
2002;99:260-266.
De P, Dryer D, Otterstatter MC, Semenciw R. Canadian
trends in liver cancer: a brief clinical and epidemiological
overview. Curr Oncol 2013;20(1):e40-43.
DeMartel C, Ferlay J, Fanceschi S, Vignat J, Bray F, Forman
D, Plummer M. Global burden of cancers attributable to
infections in 2008: a review and synthetic analysis. Lancet
Onology 2012;13:607-15.
Dewailly E, Mulvad G, Pedersen HS, Hansen JC, Behrendt
N, Hansen JPH. Inuit are protected against prostate can-
cer. Cancer Epidemiol Biomarkers Prev 2003;12:926–927.
Donaldson SG, Van Oostdam J, Tikhonov C, Feeley M,
Armstrong B, Ayotte P et al. Environmental contaminants
and human health in the Canadian Arctic. Science of the
Total Environment 2010;408:5165-5234.
Egeland GM. 2010. International Polar Year Inuit Health
Survey 2007-2008: Nunavut Health Report. Montreal:
McGill University. Source: http://inuithealthsurvey.ca/
pdf/Adult%20Report_NUNAVUT.pdf
Ellison LF, Wilkins K. Canadian trends in cancer preva-
lence. Health Rep 2012;23(1):7-16.
Flood A, Rastogi T, Wifalt E, Mitrou PN, Reedy J, Subar AF,
Kipnis V, Mouw T, Hollenbeck AR, Leitzmann M,
Schatzkin. Dietary patterns as identified by factor analysis
and colorectal cancer among middle-aged Americans. Am
J Clin Nutri 2008;88:176-84.
Friborg J , Melbye M. Cancer patterns in Inuit popula-
tions. Lancet Onology 2008;9:892-900.
Friborg J, Wohlfahrt J, Koch A, Storm H, Olsen OR , Mel-
bye M. Cancer Susceptibility in Nasopharyngeal Carcino-
ma Families—A Population-Based Cohort Study. Cancer-
Research 2005;65(18):8567-72.
Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB,
Maisonneuve P , Boyle P. Tobacco smoking and cancer: a
meta-analysis. Inter. J. Cancer 2008;122:155-164.
Gillison ML, Koch WM, Capone RB, Spafford M, Westra
WH, Wu L, ahurak ML, Daniel RW, Viglione M, Symer DE,
Shah KV, Sidransky D. Evidence for a causal association
between Human Papillomavirus and a subset of head and
neck cancers. Journal of the National Cancer Institute
2000;92(9):709-720.
30
Giwercman C, Giwercman A, Pedersen HS, et al. Polymor-
phisms in genes regulating androgen activity among pros-
tate cancer low risk Inuit men and high-risk Scandinavi-
ans. Int J Androl 2008;31:25–30.
Gorlova OY, Weng S-F, Zhang Y, et al. DNA repair capacity
and lung cancer risk in never smokers. Cancer Epidemiol
Biomarkers Prev 2008;17(6):1322–8.
Greiser CM, Greiser EM, Doren M. Menopausal hormone
therapy and risk of lung cancer-Systematic review and
metaanalysis. Maturitas 2010;65(3):198–204.
Hackshaw AK, Law MR, Wald NJ. The accumulated evi-
dence on lung cancer and environmental tobacco smoke.
BMJ 1997;315(7114):980–8.
Harriss DJ, Atkinson A, Batterham A, George K, Cable NT,
Reilly T, Haboubi N, Renehan AG, The Colorectal Cancer,
Lifestyle, Exercise And Research Group. Lifestyle factors
and colorectal cancer risk (2): a systematic review and
meta-analysis of associations with leisure-time physical
activity. Colorectal Disease 2009;11:689-704.
Harvald B. Genetic epidemiology of Greenland. Clinical
Genetics 1989;36(5):364-637.
Healey SM, Aronson KJ, Mao Y, Schlect NF, Mery LS,
Ferenczy A , Franco EL. Oncogenic human papillomavirus
infection and cervical lesions in Aboriginal women of Nu-
navut. Canada. Sexually Transmitted Diseases
2001;28:694 -700.
Hegedus, L. The Thyroid Nodule. New England Journal of
Medicine 2004;351:1764-71.
Hernandez-Boussard TM, Hainaut P. A specific spectrum
of p53 mutations in lung cancer from smokers: review of
mutations compiled in the IARC p53 database. Environ
Health Perspect 1998;106(7):385–91.
Hidiroglou N, Peace RW, Jee P, Leggee D , Kuhnlein H.
Levels of folate, pyridoxine, niacin and riboflavin in tradi-
tional foods of Canadian Arctic indigenous peoples. Jour-
nal of Food Composition and Analysis 2008;1:74-480.
Holmes RS , Vaughan TL. Epidemiology and Pathogenesis
of Esophageal Cancer. Sem Radiat Oncol 2007;7:2-9.
Huxley T, Ansary-Moghaddam A, de Gonzalez AB, Barzi F ,
Woodward M. Type-II diabetes and pancreatic cancer: a
meta-analysis of 36 studies. British Journal of Cancer
2005;92:2076-2083.
Huet C, Rosol R , Egeland GM. The prevalence of food
insecurity is high and the diet quality poor in Inuit com-
munities. J Nutr 2012;142:541-547.
Inuit Tapiriit Kanatami. Inuit-specific tuberculosis strate-
gy. March 2013.
Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radi-
ce P, Bernard L, Maisonneuve P , Gandini S. Oral contra-
ceptive use and breast or ovarian cancer risk in BRCA1/2
carriers: A meta-analysis. European Journal of Cancer
2010;46:3386-2284.
Kanda J, Matsuo K, Kawase T, Suzuki T, Ichinohe T, Seto
M, Morishima Y, Tajima K , Tanaka H. Association of alco-
hol intake and smoking with malignant lymphoma risk in
Japanese: A hospital-based case-control study at Aichi
Cancer Centre. Cancer Epidemiol Biomarkers Prev
2009;18(9):2436-2441.
Karafet TM, Zegura SL, Posukh O, Osipova L, Bergen A,
Long J, Goldman D, Klitz W, Harihara S, de Knijff P, Wiebe
V, Griffiths RC, Templeton AR , Hammer MF. Ancestral
Asian Source(s) of New World Y– Chromosome Founder
Haplotypes. American Journal of Human Genetics
1999;64:817-31.
Kelley JR , Duggan JM. Gastric cancer epidemiology and
risk factors. Journal of Clinical Epidemiology 2003;56:1-9.
Kleinerman RA. Cancer risk following diagnostic and ther-
apeutic radiation exposure in children. Pediatr Radiol
2006;36(2):121-125.
Koch A, Krause TG, Krogfelt K, Olsen OR, Fischer TK , Mel-
bye M. Seroprevalence and Risk Factors for Helicobacter
pylori Infection in Greenlanders. Helicobacter 2005;10
(5):433-42.
Kuhnlein HV, Barthet V, Farren A, Falahi E, Leggee D,
Receveur O et al. Vitamins A, D, and E in Canadian Arctic
traditional food and adult diets. Journal of Food Composi-
tion and Analysis 2006;19:495-506.
Kuhnlein HV, Chan HM, Legge D , Barthet V. Macronutri-
ent, mineral and fatty acid composition of Canadian Arc-
tic traditional food. Journal of Food Composition and
Analysis 2002;15:545-566.
Kuhnlein HV, Receveur O, Soueida R, Egeland GM. Arctic
indigenous peoples experience the nutrition transition
with changing dietary patterns and obesity. J Nutr 2004;
134(6):1447-53.
Lanier AP, Kelly JJ, Smith B, Harpster AP, Tanttila H,
Amadon C, Beckworth D, Key C, Davidson AM. Alaska
native cancer update: incidence rates 1989–1993. Cancer
Epidemiol Biomarkers Prev 1996;5:749–51.
Cancer in Nunavut: 1999-2011 31
Larsson SC, Orsini N , Wolk A. Diabetes mellitus and risk
of colorectal cancer: a meta-analysis. Journal of the Na-
tional Cancer Institute 2005;97(22):1679-1687.
Larsson SC , Wolk A. Overweight, obesity and risk of liver
cancer: a meta-analysis of cohort studies. British Journal
of Cancer 2007;97:1005-1008.
Li D, Xie K, Wolff R , Abbruzzese JL. Pancreatic cacner.
Lancet 2004;363:1049-57.
Lissowska J, Foretova L, Dabek J, et al. Family history and
lung cancer risk: international multicentre case-control
study in Eastern and Central Europe and meta-analyses.
Cancer Causes Control 2010;21(7):1091–104.
Luo ZC, Wilkins R, Platt RW, Kramer MS. Risks of adverse
pregnancy outcomes among Inuit and North American
Indian women in Quebec, 1985-97. Paediatr Perinat Epi-
demiol 2004; 18: 40-50.
Maitra A , Hruban RH. Pancreatic Cancer. Annu Rev
Pathol 2009;3:157-188.
Mammas IN, Sourvinos G, Zaravinos A , Spandidos DA.
Vaccination against human papilloma virus (HPV): epide-
miological evidence of HPV in non-genital cancers. Pathol
Oncol Res 2011;17:103-119.
Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K ,
Mueller NE. Effect of hepatitis C virus infection on the
risk of non-Hodgkin’s lymphoma: A meta-analysis of epi-
demiological studies. Cancer Sci 2004;95(9):745-752.
McDonald JT , Trenholm R. Cancer-related health behav-
iours and health service use among Inuit and other resi-
dents of Canada’s north. Social Science & Medicine
2010;70:1396-1403.
Moghaddam AA, Woodward M , Huxley R. Obesity and
risk of colorectal cancer: A meta-analysis of 31 studies
with 70,000 events. Cancer Epidemiol Biomarkers Prev
2007;16:2533-2547.
McKeown I, Orr P, Macdonald S, Kabani A, Brown R,
Coghlan G, Dawood M, Embil J, Sargent M, Smart G,
Bernstein CN. Helicobacter pylori in the Canadian arctic:
Seroprevalence and detection in community water sam-
ples. Am J Gastroenterol 1999;94:1823–9.
Meinhold CL, Ron E, Schonfeld SJ, Alexander BH, Freed-
man DM, Linet MS, de Gonzalez AB. Nonradiation risk
factors for Thyroid Cancer in the US Radiologic Technolo-
gists Study. American Journal of Epidemiology 2009;171
(2):242-252.
Melbye M, Ebbgesen P, Levine PH , Bennike T. Early pri-
mary infection and high Epstein-barr virus antibody titers
in Greenland Eskimos at high risk for nasopharyngeal
carcinoma. International Journal of Cancer 1984;34
(5):619-23.
Minuk GY , Uhanova J. Viral hepatitis in the Canadian
Inuit and First Nations populations. Can J Gastroenterolo-
gy 2003;17(12):707-712.
Narod SA. Modeifiers of risk of hereditary breast cancer.
Oncogene 2006;25:5832-36.
Nordenstedt H, White DL , El-Serag HB. The changing
pattern of epidemiology in hepatocellular carcinoma. Dig
Liver Dis 2010;42(3):S206-214
Parkin DM, Wheelan SL, Ferlay J, Teppo L, Thomas D.
Cancer incidence in five continents. Volume VIII. Lyon:
IARC Scientific Publications, 2002.
Polesel J, Franceschi S, Talamini R, Negri E, Barzan L,
Montella M, Libra M, Vaccher E, Franchin G, La Vecchia
C , Serraino D. Tobacco smoking, alcohol drinking, and
the risk of different histological types of nasopharyngeal
cancer in a low-risk population. Oral Oncology
2011;47:541-545.
Population Health Information, Department of Health,
Government of Nunavut. Iqaluit, Nunavut: 2012.
Public Health Agency of Canada. Canada Communicable
Disease Report: Statement Update on Human Papilloma-
virus (HPV) Vaccines, 38, 2012. Source: http://www.phac
-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/index-
eng.php
Public Health Agency of Canada. Tuberculosis in Canada
2011, Pre-release. Ottawa (Canada), 2012: Minister of
Public Works and Government Services Canada.
Renehan AG, Tyson M, Egger M, Heller RF , Swahlen M.
Body-mass index and incidence of cancer: a systematic
review and meta-analysis of prospective observational
studies. Lancet 2008;371:569-78.
Reulen RC, Kellen E, Buntinx F, Brinkman M , Zeegers MP.
A meta-analysis on the association between bladder can-
cer and occupation. Scandinavian Journal of Urology and
Nephrology 2008;42(218):64-78.
Russo AL, Chen M, Aizer AA, Hattangadi JA , D’Amico AV.
Advancing age within established Gleason score catego-
ries and the risk of prostate cancer-specific mortality. BJU
International 2012;110:973-979.
32
Schottenfeld D , Beebe-Dimmer J. Chronic Inflammation:
a Common and important factor in the pathogenesis of
neoplasia. CA Cancer J Clin 2006;56(2):69-83.
Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ,
Madeleine MM, et al. Oral cancer risk in relation to sexu-
al history and evidence of human papillomavirus infec-
tion. J Natl Cancer Inst 1998;90:1626–1636.
Sheikh N, Egeland GM, Johnson-Down L , Kuhnlein HV.
Changing dietary patterns and body mass index over
time in Canadian Inuit communities. Int J Circumpolar
Health 2011;70(5):511-519.
Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11.
Shi C, Hruban RH, Klein AP. Familial pancreatic cancer.
Arch Pathol Lab Med 2009;133:365-74.
Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winter
R , Cliifford GM. Human papillomavirus type distribution
in invasive cervical cancer and high-grade cervical le-
sions: A meta-analysis update. Int J Cancer 2007;121:621-
632.
Snyder OB, Kelly JJ, Lanier AP. Prostate cancer in Alaska
Native men, 1969–2003. Int J Circumpolar Health
2006;65:8–17.
Sotiriou C , Pusztai L. Gene-expression signatures in
breast cancer. N Engl J Med 2009;360:790-800.
Spence AR, Goggin P, Franco EL: Process of care failures
in invasive cervical cancer: systematic review and meta-
analysis. Prev Med 2007;45:93–106.
Statistics Canada, 2011 Census of Population, Statistics
Canada Catalogue no. 98-313-XCB2011023. http://
www12.statcan.gc.ca/census-recensement/2011/dp-pd/
tbt-tt/Rp-eng.cfm?
LANG=E&APATH=3&DETAIL=1&DIM=1&FL=A&FREE=0&G
C=0&GID=0&GK=0&GRP=1&PID=102237&PRID=0&PTYPE
=101955&S=0&SHOWALL=0&SUB=0&Temporal=2011&T
HEME=91&VID=20749&VNAMEE=&VNAMEF=
Statistics Canada. Table 102-4505: Crude birth rate, age-
specific and total fertility rates (live births), Canada, prov-
inces and territories. Source: http://www5.statcan.gc.ca/
cansim/a26?
lang=eng&retrLang=eng&id=1024505&tabMode=dataTa
ble&srchLan=-1&p1=-1&p2=9
Statistics Canada. Table 102-0563: Leading causes of
death, total population, by sex, Canada, provinces and
territories. Source: http://www5.statcan.gc.ca/cansim/
a26?
lang=eng&retrLang=eng&id=1020563&tabMode=dataTa
ble&srchLan=-1&p1=-1&p2=9
Statistics Canada. Table102-0706: Life expectancy, at
birth and at age 65, by sex, five-year average, Canada
and Inuit regions, every 5 years (years), CANSIM
(database). Source: http://www5.statcan.gc.ca/cansim/
a26?
lang=eng&retrLang=eng&id=1020706&tabMode=dataTa
ble&srchLan=-1&p1=-1&p2=9
Statistics Canada. Table 103-0553: New cases and age-
standardized rate of ICD-O-3 primary sites of cancer
(based on the July 2011 CCR tabulation file), by sex, Can-
ada, provinces and territories. Source:
www5.statcan.gc.ca/cansim/a26?
lang=eng&retrLang=eng&id=1030553&tabMode=dataTa
ble&srchLan=-1&p1=-1&p2=9
Statistics Canada. Table 105-0503: Health indicator pro-
file, age-standardized rate, annual estimates, by sex, Can-
ada, provinces and territories. Source: http://
www5.statcan.gc.ca/cansim/a26?
lang=eng&retrLang=eng&id=1050503&tabMode=dataTa
ble&srchLan=-1&p1=-1&p2=9
Statistics Canada. Table 105-0513: Health indicator pro-
file, by Aboriginal identity and sex, age-standardized rate,
four year estimates, Canada, provinces and territories.
Source: http://www5.statcan.gc.ca/cansim/a26?
lang=eng&retrLang=eng&id=1050513&tabMode=dataTa
ble&srchLan=-1&p1=-1&p2=9
Tait, H. Aboriginal People`s Survey, 2006: Inuit Health
and Social Conditions. Ottawa ON: Statistics Canada.
Source: http://www.statcan.gc.ca/pub/89-637-x/89-637-
x2008001-eng.pdf
Taylor R, Najafi F, Dobson A. Meta-analysis of studies of
passive smoking and lung cancer: effects of study type
and continent. International Journal of Epidemiology
2007;36:1048-1059.
Terry P, Lichtenstein P, Feychting M, Ahlbom A, Wolk A.
Fatty fish consumption and risk of prostate cancer. Lan-
cet 2001;357:1764–66.
Tofflemire KM. Respiratory Health of Inuit Stone Carvers.
Thesis (MHSc) - University of Alberta, 2003.
Cancer in Nunavut: 1999-2011 33
Tramacere I, Pelucchi C, Bagnardi V, Rota M, Scotti L,
Islami F, Corrao G, Boffetta P, La Vecchia C , Negri E. A
meta-analysis on alcohol drinking and esophageal and
gastric cardia adeno carcinoma risk. Annals of Oncology
2012;23:287-97.
Tran GD, Sun XD, Abnet CC, Fan J, Dawsey SM, Dong Z,
Mark SD, Qiao Y , Taylor PR. Prospective study of risk
factors for esophageal and gastric cancers in the Linxian
general population trial cohort in China. Int J Cancer
2005;113:456-463.
Wang Y, Wang B, Shen F, Fan J , Cao H. Body Mass Index
and risk of primary liver cancer: A meta-analysis of pro-
spective studies. The Oncologist 2012;28:1461-1468.
Yu I, Chiu Y, Au J, Wong T, Tang JL. Dose–response rela-
tionship between cooking fumes exposures and lung can-
cer among Chinese nonsmoking women. Cancer Res
2006;66:4961–67.
Yu Y, Yang A, Hu S, Yan H. Correlation of HPV-16/18 infec-
tion of human papillomavirus with lung squamous cell
carcinomas in Western China. Oncol Rep 2009;21:1627–
1632.
Zhang L, Steinmaus C, Eastmond DA, Xin XK , Smith MT.
Formaldehyde exposure and leukemia: A new meta-
analysis and potential mechanisms. Mutat Res 2008;681:
150-168.
34
The Canadian Cancer Registry (CCR): Incident Data
Population Health Information in collaboration with Cancer
Care Ontario identifies incident cancer cases; this data is then
provided to the Health Statistics Division at Statistics Canada.
Nunavut data is available for 1999-2011, with 2011 cases being
provisional. National data is available from 1984 to 2007, with
data from 2008 and onwards being projections done by the
Public Health Agency of Canada.
The CCR provides data on demographic and clinical factors.
Patients are registered according to jurisdiction of residence at
the time of diagnosis. The database is structured to prevent
duplicate person or tumor entry. This information is also linked
with mortality data to ensure database completeness. Cancer
is classified using the International Classification of Diseases for
Oncology, 3rd revision (ICD-O-3).
Limitations: (1) missing data due to out of territory diagnosis
and difficulty in case finding, and (2) timeliness of data, there is
an 18-month delay on data release.
The Canadian Vital Statistics death database
(CVS:D): Mortality Data
The Nunavut Vital Statistics office registers territorial deaths;
this data is provided to the Health Statistics Division at Statis-
tics Canada for inclusion in the CVS:D.
The CVS:D provides data on demographics and cause of death
for residents who died between 1950-2009; cancer mortality
data is available for the period of 1984 to 2009. Nunavut death
clearance data is available from 1999 to 2008.
Cause of death is classified using the International Statistical
Classification of Diseases and Related Health Problems, 10th
revision (ICD-10). To be classified as a cancer death it needs to
be certified by a physician.
Limitations: (1) missing data due to out of territory deaths sec-
ondary to lack of territorial tertiary facilities, (2) timeliness of
data due to out of territory deaths and completing autopsy
reports, and (3) misclassification of cause of death during certi-
fication process resulting in the possible underreporting of
deaths attributable to cancer.
Population Data: Nunavut and Canada
Population projections based on the 5-year national census
data obtained from the Nunavut Bureau of Statistics was used
for the Nunavut population. Population projections based on
the 5-year national census data from Statistics Canada was
used for the Canadian population.
Limitations: Assumptions of growth for projection calculations.
The Canadian Community Health Survey (CCHS):
Risk Factor Data
CCHS is a national, cross-sectional, self-report survey targeting
Canadians 12 years and older. From 2000 to 2005 it was con-
ducted every two years; from 2007 onward it has been done
annually. In Nunavut, 350 individuals from 10 communities
(Iqaluit, Rankin Inlet, Cambridge Bay, Kugluktuk, Cape Dorset,
Igloolik, Pond Inlet, Baker Lake and Arviat) are surveyed each
year providing a 71% coverage rate.
Limitations: (1) non-representative sample and biased infor-
mation due to non-random community selection, (2) self-
report bias, and (3) small sample size.
Inuit Health Survey (IHS): Risk Factor Data
IHS is a cross-sectional, health status survey conducted in Inuit-
inhabited areas of Canada excluding Quebec in 2007 and 2008.
There were 33 coastal and three inland communities targeted.
In Nunavut, 1,923 residents 18 years and older and self-
identified as Inuit were surveyed in 25 communities. An aver-
age of 1.4 people per household participated.
Limitations: (1) Cross-sectional design, (2) self-report bias, and
(3) exclusion of homeless population.
Community Health Service Records (CHSR): Com-
munity Health Centre Visits
The CHSR is an administrative database. When an individual
accesses a health centre, the practitioner completes a CHSR
form listing the reason for accessing services and the ICD-10
code. These forms are then mailed to Iqaluit for entry into the
database.
Limitations: (1) Incorrect codes, (2) incomplete forms, (3)
missing information, and (4) data entry error.
Appendix A: Data sources and Limitations
Cancer in Nunavut: 1999-2011 35
Appendix B: Cancer site classification: ICD-O-3
Cancer ICD-O-3 Code Oral C00-11
Other buccal cavity & pharynx C09, C12-14
Esophagus C15
Stomach C16
Colorectal C18-20, C26.0
Liver C22.0
Pancreas C25
Other digestive system including small intestine and anal
C17, C21, C22.1, C24, C26.8-26.9, C48.0-48.8
Larynx C32
Lung C34
Other respiratory system C30.0-30.1, C31, C33.9, C38.1-38.8, C39
Melanoma C44 (Type 8720-8790)
Other Skin C44
Breast C50
Cervix C53
Body of uterus C54-55
Ovary C56.9
Other female genital C51, C52.9, C57-58
Prostate C61.9
Testis C62
Other male genital C63
Bladder (including in situ) C67
Kidney C64.9, C65.9
Other urinary system C66.9, C68
Brain C70-72
Thyroid C73.9
Other endocrine C37.9, C74, C75
Hodgkin Lymphoma Type 9650–9667
Non-Hodgkin Lymphoma Type 9590–9597, 9670–9719, 9724–9729, 9735, 9737, 9738, 9811–9818, 9823, 9827, 9837 all sites except C42.0,.1,.4
Other lymph C77
Multiple Myeloma Type 9731, 9732, 9734
Leukemia Type 9733, 9742, 9800–9801, 9805–9809, 9820, 9826, 9831–9836, 9840, 9860–9861, 9863, 9865–9867, 9869–9876, 9891, 9895–9898, 9910, 9911, 9920, 9930–9931, 9940, 9945–9946, 9948, 9963–9964, Type 9811–9818, 9823, 9827, 9837 sites C42.0,.1,.4
Bones and joints C40-41
Soft tissue C38.0, C47, C49
Unknown C42.0-42.4, M-8000 to M-9049, M-9056 to M-9139, M-9141 to M-9589; C76.0-76.8, M-8000 to M-9049, M-9056 to M-9139, M-9141 to M-9589; C77.0-77.9, M-8000 to M-9049, M-9056 to M-9139, M-9141 to M-9589; C80.9, M-8000 to M-9049, M-9056 to M-9139, M-9141 to M-9589; M-9740, M-9741, M-9750 to M-9758, M-9760 to M-9769, M-9950 to M-9962, M-9970 to M-9989
36
Appendix C: Methodology
Age Statistics
For age, the mean is provided as a summary measure for esti-
mates that have a normal distribution. In cases where the
data is skewed the median is provided.
Confidence intervals and statistical significance
Confidence intervals are a measure of variability; when avail-
able the 95% confidence interval is provided in square brack-
ets next to the estimate.
The confidence interval overlap method was used to deter-
mine statistical significance in rate comparisons. The confi-
dence intervals for rate comparisons were calculated using
the Fleiss method.
Three-year moving average
A three-year, simple moving average for Nunavut ASIR data
was used to smooth trends and facilitate interpretation.
Incidence rates: Nunavut & Canada
Nunavut incident rates were calculated from the territorial
cancer registry which is collaboratively maintained with Can-
cer Care Ontario. The 2011 data is considered provisional.
Canadian incident rates were calculated from the CCR.
The cancer registry is a dynamic database, thus incidence
rates may change as more data becomes available.
Age-standardized incident rate (ASIR)
Incident data was standardized to the 1991 Canadian popula-
tion using the direct method. The direct method involves
weighting the ASIRs for each 5-year age group according to
the age distribution of the 1991 Canadian population.